# Systematic Dementia Screening by Multidisciplinary Team Meetings in Nursing Homes for Reducing Emergency Department Transfers

Yves Rolland, Neda Tavassoli, Philipe de Souto Barreto, Amélie Perrin, Clarisse Laffon de Mazières, Thomas Rapp, Sophie Hermabessière, Elodie Tournay, Bruno Vellas, Sandrine Andrieu

► To cite this version:

Yves Rolland, Neda Tavassoli, Philipe de Souto Barreto, Amélie Perrin, Clarisse Laffon de Mazières, et al.. Systematic Dementia Screening by Multidisciplinary Team Meetings in Nursing Homes for Reducing Emergency Department Transfers: The IDEM Cluster Randomized Clinical Trial. JAMA Network Open, 2020, 3 (2), pp.e200049. 10.1001/jamanetworkopen.2020.0049. hal-04538705

HAL Id: hal-04538705

https://hal.science/hal-04538705

Submitted on 9 Apr 2024

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>
<figure><img src="image_1.png" /></figure>

**Original Investigation** | Geriatrics

# Systematic Dementia Screening by Multidisciplinary Team Meetings in Nursing Homes for Reducing Emergency Department Transfers
## The IDEM Cluster Randomized Clinical Trial

Yves Rolland, MD, PhD; Neda Tavassoli, PharmD, PhD; Philippe de Souto Barreto, PhD; Amélie Perrin, MD; Clarisse Laffon de Mazières, MD; Thomas Rapp, PhD; Sophie Hermabessière, MD; Elodie Tournay, PhD; Bruno Vellas, MD, PhD; Sandrine Andrieu, MD, PhD

## Abstract

**IMPORTANCE** Dementia is often underdiagnosed in nursing homes (NHs). This potentially results in inappropriate care, and high rates of emergency department (ED) transfers in particular.

**OBJECTIVE** To assess whether systematic dementia screening of NH residents combined with multidisciplinary team meetings resulted in a lower rate of ED transfer at 12 months compared with usual care.

**DESIGN, SETTING, AND PARTICIPANTS** Multicenter, cluster randomized trial with NHs as the unit of randomization. The IDEM (Impact of Systematic Tracking of Dementia Cases on the Rate of Hospitalization in Emergency Care Units) trial took place at 64 public and private NHs in France. Recruitment started on May 1, 2010, and was completed on March 31, 2012. Residents who were aged 60 years or older, had no diagnosed or documented dementia, were not bedridden, had lived in the NH for at least 1 month at inclusion, and had a life expectancy greater than 12 months were included. The residents were followed up for 18 months. The main study analyses were completed on October 14, 2016.

**INTERVENTION** Two parallel groups were compared: an intervention group consisting of NHs that set up 2 multidisciplinary team meetings to identify residents with dementia and to discuss an appropriate care plan, and a control group consisting of NHs that continued their usual practice. During the inclusion period of 23 months, all residents of participating NHs who met eligibility criteria were included in the study.

**MAIN OUTCOMES AND MEASURES** The primary end point (ED transfer) was analyzed at 12 months, but the residents included were followed up for 18 months.

**RESULTS** A total of 64 NHs participated in the study and enrolled 1428 residents (mean [SD] age, 84.7 [8.1] years; 1019 [71.3%] female): 599 in the intervention group (32 NHs) and 829 in the control group (32 NHs). The final study visit was completed by 1042 residents (73.0%). The main reason for early discontinuation was death (318 residents [22.7%]). The intervention did not reduce the risk of ED transfers during the 12-month follow-up: the proportion of residents transferred at least once to an ED during the 12-month follow-up was 16.2% in the intervention group vs 12.8% in the control group (odds ratio, 1.32; 95% CI, 0.83-2.09; P = .24).

**CONCLUSIONS AND RELEVANCE** This study failed to demonstrate that systematic screening for dementia in NHs resulted in fewer ED transfers. The findings do not support implementation of

(continued)

## Key Points

**Question** Does systematic dementia screening of nursing home residents combined with multidisciplinary team meetings result in a lower rate of emergency department transfer compared with usual care?

**Findings** In this cluster randomized clinical trial that included 1428 residents in 64 nursing homes, 16.2% of residents in the intervention group were transferred to emergency departments vs 12.8% in the control group during the 12-month follow-up, a nonsignificant difference.

**Meaning** This study does not suggest that systematic screening for dementia in all nursing home residents reduces emergency department transfers.

## Visual Abstract

## Supplemental content

Author affiliations and article information are listed at the end of this article.

<figure><img src="image_2.png" /></figure>

Open Access. This is an open access article distributed under the terms of the CC-BY License.
<figure><img src="image_2.png" /></figure>

**Original Investigation** | Geriatrics

# Systematic Dementia Screening by Multidisciplinary Team Meetings in Nursing Homes for Reducing Emergency Department Transfers
## The IDEM Cluster Randomized Clinical Trial

Yves Rolland, MD, PhD; Neda Tavassoli, PharmD, PhD; Philippe de Souto Barreto, PhD; Amélie Perrin, MD; Clarisse Laffon de Mazières, MD; Thomas Rapp, PhD; Sophie Hermabessière, MD; Elodie Tournay, PhD; Bruno Vellas, MD, PhD; Sandrine Andrieu, MD, PhD

## Abstract

**IMPORTANCE** Dementia is often underdiagnosed in nursing homes (NHs). This potentially results in inappropriate care, and high rates of emergency department (ED) transfers in particular.

**OBJECTIVE** To assess whether systematic dementia screening of NH residents combined with multidisciplinary team meetings resulted in a lower rate of ED transfer at 12 months compared with usual care.

**DESIGN, SETTING, AND PARTICIPANTS** Multicenter, cluster randomized trial with NHs as the unit of randomization. The IDEM (Impact of Systematic Tracking of Dementia Cases on the Rate of Hospitalization in Emergency Care Units) trial took place at 64 public and private NHs in France. Recruitment started on May 1, 2010, and was completed on March 31, 2012. Residents who were aged 60 years or older, had no diagnosed or documented dementia, were not bedridden, had lived in the NH for at least 1 month at inclusion, and had a life expectancy greater than 12 months were included. The residents were followed up for 18 months. The main study analyses were completed on October 14, 2016.

**INTERVENTION** Two parallel groups were compared: an intervention group consisting of NHs that set up 2 multidisciplinary team meetings to identify residents with dementia and to discuss an appropriate care plan, and a control group consisting of NHs that continued their usual practice. During the inclusion period of 23 months, all residents of participating NHs who met eligibility criteria were included in the study.

**MAIN OUTCOMES AND MEASURES** The primary end point (ED transfer) was analyzed at 12 months, but the residents included were followed up for 18 months.

**RESULTS** A total of 64 NHs participated in the study and enrolled 1428 residents (mean [SD] age, 84.7 [8.1] years; 1019 [71.3%] female): 599 in the intervention group (32 NHs) and 829 in the control group (32 NHs). The final study visit was completed by 1042 residents (73.0%). The main reason for early discontinuation was death (318 residents [22.7%]). The intervention did not reduce the risk of ED transfers during the 12-month follow-up: the proportion of residents transferred at least once to an ED during the 12-month follow-up was 16.2% in the intervention group vs 12.8% in the control group (odds ratio, 1.32; 95% CI, 0.83-2.09; P = .24).

**CONCLUSIONS AND RELEVANCE** This study failed to demonstrate that systematic screening for dementia in NHs resulted in fewer ED transfers. The findings do not support implementation of

(continued)

## Key Points

**Question** Does systematic dementia screening of nursing home residents combined with multidisciplinary team meetings result in a lower rate of emergency department transfer compared with usual care?

**Findings** In this cluster randomized clinical trial that included 1428 residents in 64 nursing homes, 16.2% of residents in the intervention group were transferred to emergency departments vs 12.8% in the control group during the 12-month follow-up, a nonsignificant difference.

**Meaning** This study does not suggest that systematic screening for dementia in all nursing home residents reduces emergency department transfers.

### Visual Abstract

### Supplemental content

Author affiliations and article information are listed at the end of this article.

<figure><img src="image_3.png" /></figure>

Open Access. This is an open access article distributed under the terms of the CC-BY License.
Abstract (continued)

multidisciplinary team meetings for systematic dementia screening of all NH residents, beyond the
national recommendations for dementia diagnosis, to reduce ED transfers.

TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT01569997

JAMA Network Open. 2020;3(2):e200049. doi:10.1001/jamanetworkopen.2020.0049

Introduction

In populations with multiple underlying morbidities, such as nursing home (NH) residents, dementia is highly prevalent and frequently associated with potentially avoidable adverse events, including falls, weight loss, delirium, side effects of polymedication, and behavioral disturbances. Although systematic screening for dementia in NH residents¹ is recommended by expert groups and by guidelines, underrecognition of the disease has been repeatedly reported in Europe and in the United States² and has been identified as an indicator of poor-quality care.³ Underdiagnosis of dementia has resulted in inappropriate health care⁴⁻⁷ and, in particular, a high hospitalization rate, notably emergency department (ED) admissions. However, to our knowledge, the hypothesis that dementia screening in NH residents results in a lower ED transfer rate has never been demonstrated.

The aim of this cluster randomized clinical trial was to assess whether systematic dementia screening in NH residents, combined with multidisciplinary team meetings (MDTMs), resulted in a lower ED transfer rate compared with usual care.

Methods

The IDEM (Impact of Systematic Tracking of Dementia Cases on the Rate of Hospitalization in Emergency Care Units) study was a multicenter study cluster randomized by NH (1:1) that compared 2 groups: an intervention group consisting of NHs that set up MDTMs to identify residents with dementia and to propose an appropriate care plan, and a control group of NHs that continued their usual practice. The cluster randomized design was chosen for this study because it was difficult to include residents in both intervention and control groups in the same NH without the risk of contamination between the 2 groups. Recruitment started on May 1, 2010, and was completed on March 31, 2012. The residents were followed up for 18 months. The main study analyses were completed on October 14, 2016. The study protocol (available in Supplement 1) was approved by the French Ethics Committee for the Protection of Persons and the competent authority located in Toulouse. Oral informed consent for study participation was obtained from all residents or their representatives by the NH coordinating physicians (more details about the role of the coordinating physician appear in eAppendix 1 in Supplement 2). Participants' written informed consent was not required by French law at the time of the study. This study followed the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline.

Cluster Randomization

The unit of randomization was the NH. Before starting resident recruitment, cluster randomization
with a 1:1 ratio was performed using STATA software version 9 (StataCorp LP) to allocate NHs to the
intervention or the control group (stratification criteria appear in eAppendix 2 in Supplement 2).

Inclusion and Exclusion Criteria

Nursing homes located in various regions of France participated in the study on a voluntary basis.
There were no exclusion criteria for nursing home participation. When the project was set up, the

<figure><img src="image_3.png" /></figure>
Abstract (continued)

multidisciplinary team meetings for systematic dementia screening of all NH residents, beyond the
national recommendations for dementia diagnosis, to reduce ED transfers.

TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT01569997

JAMA Network Open. 2020;3(2):e200049. doi:10.1001/jamanetworkopen.2020.0049

Introduction

In populations with multiple underlying morbidities, such as nursing home (NH) residents, dementia is highly prevalent and frequently associated with potentially avoidable adverse events, including falls, weight loss, delirium, side effects of polymedication, and behavioral disturbances. Although systematic screening for dementia in NH residents¹ is recommended by expert groups and by guidelines, underrecognition of the disease has been repeatedly reported in Europe and in the United States² and has been identified as an indicator of poor-quality care.³ Underdiagnosis of dementia has resulted in inappropriate health care⁴⁻⁷ and, in particular, a high hospitalization rate, notably emergency department (ED) admissions. However, to our knowledge, the hypothesis that dementia screening in NH residents results in a lower ED transfer rate has never been demonstrated.

The aim of this cluster randomized clinical trial was to assess whether systematic dementia screening in NH residents, combined with multidisciplinary team meetings (MDTMs), resulted in a lower ED transfer rate compared with usual care.

Methods

The IDEM (Impact of Systematic Tracking of Dementia Cases on the Rate of Hospitalization in Emergency Care Units) study was a multicenter study cluster randomized by NH (1:1) that compared 2 groups: an intervention group consisting of NHs that set up MDTMs to identify residents with dementia and to propose an appropriate care plan, and a control group of NHs that continued their usual practice. The cluster randomized design was chosen for this study because it was difficult to include residents in both intervention and control groups in the same NH without the risk of contamination between the 2 groups. Recruitment started on May 1, 2010, and was completed on March 31, 2012. The residents were followed up for 18 months. The main study analyses were completed on October 14, 2016. The study protocol (available in Supplement 1) was approved by the French Ethics Committee for the Protection of Persons and the competent authority located in Toulouse. Oral informed consent for study participation was obtained from all residents or their representatives by the NH coordinating physicians (more details about the role of the coordinating physician appear in eAppendix 1 in Supplement 2). Participants' written informed consent was not required by French law at the time of the study. This study followed the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline.

Cluster Randomization

The unit of randomization was the NH. Before starting resident recruitment, cluster randomization
with a 1:1 ratio was performed using STATA software version 9 (StataCorp LP) to allocate NHs to the
intervention or the control group (stratification criteria appear in eAppendix 2 in Supplement 2).

Inclusion and Exclusion Criteria

Nursing homes located in various regions of France participated in the study on a voluntary basis.
There were no exclusion criteria for nursing home participation. When the project was set up, the

<figure><img src="image_4.png" /></figure>
coordinating physician of each NH designated a memory clinic in the same area where the MDTMs could be held with the NH staff.

During the inclusion period, all the residents of participating NHs who met the study criteria were included in the study: residents aged 60 years or older, without diagnosed or documented dementia, not bedridden (Groupe Iso-Ressources [GIR] score >1; GIR is the French level-of-dependence score from 1 to 6, where 1 indicates completely dependent or bedridden and 6 indicates completely independent),⁸ living in the NH for at least 1 month at inclusion, with a life expectancy of more than 1 year, and without any disease likely to jeopardize his or her participation in the study.

## Inclusion and Visits in NHs

After a 3-month preselection period, each coordinating physician participated in an inclusion visit with all the NH's eligible residents over a period of 2 months. Sociodemographic and medical data were collected by the coordinating physician in both groups during the inclusion visit. The residents in the intervention group also underwent a comprehensive geriatric assessment. The residents included were followed up for 18 months. At the end of follow-up, all residents in both groups underwent a final visit in the NH with the coordinating physician including a simplified comprehensive geriatric assessment (the tests performed at the inclusion and final visits are described in eAppendix 4 in Supplement 2).

## Intervention: MDTMs

In the intervention group, 2 MDTMs were organized for each NH with its associated memory clinic where the records of all participating residents were analyzed. The first meeting took place in the first month after the 2-month period of recruitment and the second meeting before the 12th month of the resident's follow-up. The case of each resident was thus discussed twice at an interval of approximately 1 year. The details of the MDTM organization and subjective qualitative assessment of the meetings have been reported elsewhere⁹ and appear in eAppendix 5 in Supplement 2.

## Outcomes

The primary efficacy outcome as prespecified in the protocol was ED transfer within the first 12 months of follow-up. The data for the primary outcome were collected monthly by the NH coordinating physicians and were entered in the IDEM electronic case report form. Transfers to the ED during the 18-month follow-up were analyzed as a secondary outcome. Other secondary outcomes were the proportion of residents with at least 1 hospital admission judged by experts as inappropriate at 18-month follow-up (these data were obtained in a subset of the total population for whom a hospitalization report was available) and the incidence rate of ED transfers during the 12 months and 18 months of follow-up for 100 person-years. To assess the impact of systematic dementia screening on the appropriateness of hospitalizations, hospitalizations were classified as appropriate or inappropriate using a standardized procedure (eAppendix 6 in Supplement 2).

## Changes to the Protocol

Owing to difficulties in including a sufficient number of participants in the study, the protocol was amended as follows: (1) the intensity of intervention on the primary outcome was increased by addition of a second MDTM and (2) the duration of residents' follow-up was extended from 12 months to 18 months to better clarify the effect of the second MDTM on ED transfers after 18 months of follow-up as a secondary outcome. The amendments were validated by the French Ethics Committee for the Protection of Persons and the competent authority in Toulouse.

## Statistical Analysis

The number of participants needed to meet our main objective was calculated by hypothesizing a bilateral test with an α risk of 5% and a β risk of 20% (80% power). Based on previous data,¹⁰ we estimated the incidence of ED admissions at 24% at 12 months in the control group. To detect a 30%

<figure><img src="image_4.png" /></figure>
coordinating physician of each NH designated a memory clinic in the same area where the MDTMs could be held with the NH staff.

During the inclusion period, all the residents of participating NHs who met the study criteria were included in the study: residents aged 60 years or older, without diagnosed or documented dementia, not bedridden (Groupe Iso-Ressources [GIR] score >1; GIR is the French level-of-dependence score from 1 to 6, where 1 indicates completely dependent or bedridden and 6 indicates completely independent),⁸ living in the NH for at least 1 month at inclusion, with a life expectancy of more than 1 year, and without any disease likely to jeopardize his or her participation in the study.

## Inclusion and Visits in NHs

After a 3-month preselection period, each coordinating physician participated in an inclusion visit with all the NH's eligible residents over a period of 2 months. Sociodemographic and medical data were collected by the coordinating physician in both groups during the inclusion visit. The residents in the intervention group also underwent a comprehensive geriatric assessment. The residents included were followed up for 18 months. At the end of follow-up, all residents in both groups underwent a final visit in the NH with the coordinating physician including a simplified comprehensive geriatric assessment (the tests performed at the inclusion and final visits are described in eAppendix 4 in Supplement 2).

## Intervention: MDTMs

In the intervention group, 2 MDTMs were organized for each NH with its associated memory clinic where the records of all participating residents were analyzed. The first meeting took place in the first month after the 2-month period of recruitment and the second meeting before the 12th month of the resident's follow-up. The case of each resident was thus discussed twice at an interval of approximately 1 year. The details of the MDTM organization and subjective qualitative assessment of the meetings have been reported elsewhere⁹ and appear in eAppendix 5 in Supplement 2.

## Outcomes

The primary efficacy outcome as prespecified in the protocol was ED transfer within the first 12 months of follow-up. The data for the primary outcome were collected monthly by the NH coordinating physicians and were entered in the IDEM electronic case report form. Transfers to the ED during the 18-month follow-up were analyzed as a secondary outcome. Other secondary outcomes were the proportion of residents with at least 1 hospital admission judged by experts as inappropriate at 18-month follow-up (these data were obtained in a subset of the total population for whom a hospitalization report was available) and the incidence rate of ED transfers during the 12 months and 18 months of follow-up for 100 person-years. To assess the impact of systematic dementia screening on the appropriateness of hospitalizations, hospitalizations were classified as appropriate or inappropriate using a standardized procedure (eAppendix 6 in Supplement 2).

## Changes to the Protocol

Owing to difficulties in including a sufficient number of participants in the study, the protocol was amended as follows: (1) the intensity of intervention on the primary outcome was increased by addition of a second MDTM and (2) the duration of residents' follow-up was extended from 12 months to 18 months to better clarify the effect of the second MDTM on ED transfers after 18 months of follow-up as a secondary outcome. The amendments were validated by the French Ethics Committee for the Protection of Persons and the competent authority in Toulouse.

## Statistical Analysis

The number of participants needed to meet our main objective was calculated by hypothesizing a bilateral test with an α risk of 5% and a β risk of 20% (80% power). Based on previous data,¹⁰ we estimated the incidence of ED admissions at 24% at 12 months in the control group. To detect a 30%

<figure><img src="image_5.png" /></figure>
reduction in ED transfer rate in the intervention group, with a 2-tailed test and an α risk of 5% and 80% power, 1000 participants were required in each group, taking into account an intracluster correlation coefficient of 0.02, a 20% attrition rate, and an inflation factor related to contamination between groups of 5% to 10% during a 12-month trial. By estimating a mean number of 30 inclusions per NH, 35 institutions per group were needed.

The modified intention-to-treat population, defined as all residents included who were followed up for at least 30 days, was used as the main analysis population for all efficacy end points (primary and secondary).

Descriptive statistics were presented as mean and standard deviation or absolute numbers and percentages, as appropriate. Owing to the design of the study (randomized by cluster), regression analyses at individual level that took between-cluster variation into account were performed to assess the intervention effects. For primary efficacy analysis, ED transfers during the first 12 months of follow-up were described and compared between groups using a random-effects logistic regression model, with group as the fixed effect and NH as the random effect. The intervention effect vs control was estimated by the odds ratio and its 95% confidence interval. For participants who did not complete the 12-month follow-up, the primary end point was considered as negative if no ED transfer was reported before study termination.

For the secondary outcomes, random effects logistic regression models were used to test the intervention effect on proportions. The number of times that residents were hospitalized during follow-up was modeled by random-effects negative binomial regression, and intervention effect was measured by rate ratio with its 95% confidence interval. All secondary efficacy analyses were performed at a significance level of 5% without adjustment for multiplicity (see per-protocol and exploratory analyses in eAppendix 7 and eAppendix 8 in Supplement 2).

All analyses were performed using SAS statistical software version 9.4 (SAS Institute Inc). Significance was set at 2-tailed *P* < .05.

# Results

## Descriptive Results

Eighty-nine NHs agreed to participate in the IDEM study. After cluster randomization, 44 NHs were randomized to the intervention group and 45 to the control group. However, 25 NHs (12 in the intervention group and 13 in the control group) withdrew from the study before the recruitment of the first resident (Figure). A final total of 64 randomized NHs participated in the study, 32 in the intervention group and 32 in the control group (Table 1). Overall, during the 23-month inclusion period, 1428 residents were enrolled in the study (mean [SD] age, 84.7 [8.1] years; 1019 [71.3%] female), 599 in the intervention group and 829 in the control group. In all, 1166 residents (81.7%) were followed for at least 12 months, and the final study visit at 18 months was completed by 1042 residents (73.0%); completion rates were similar between groups. The main reason for early discontinuation was death (318 residents [22.7%]) (Figure). The mean (SD) number of months of follow-up was 15.8 (4.6) in both groups.

Recruitment started on May 1, 2010, and was completed on March 31, 2012. Twenty-seven residents were excluded from the efficacy analysis: 11 in the intervention group (1.8%) and 16 in the control group (1.9%) who were followed up for less than 30 days according to the modified intention-to-treat definition. Baseline characteristics of the 1401 residents included in the modified intention-to-treat analysis (588 in the intervention group and 813 in the control group) are shown in Table 2. The results of the comprehensive geriatric assessment at inclusion and at 18-month follow-up are shown in eTable 1 in Supplement 2.

In the intervention group, the cases of 581 residents (98.8%) were presented at the first MDTM and a conclusion on dementia diagnosis was provided for 574 residents (97.6%): high probability of dementia for 129 residents (22.5%) and suspicion of dementia for 107 residents (18.6%). In 462 cases (79.5%) presented at the first MDTM, the residents' general practitioners (GPs) were informed of the

<figure><img src="image_5.png" /></figure>
reduction in ED transfer rate in the intervention group, with a 2-tailed test and an α risk of 5% and 80% power, 1000 participants were required in each group, taking into account an intracluster correlation coefficient of 0.02, a 20% attrition rate, and an inflation factor related to contamination between groups of 5% to 10% during a 12-month trial. By estimating a mean number of 30 inclusions per NH, 35 institutions per group were needed.

The modified intention-to-treat population, defined as all residents included who were followed up for at least 30 days, was used as the main analysis population for all efficacy end points (primary and secondary).

Descriptive statistics were presented as mean and standard deviation or absolute numbers and percentages, as appropriate. Owing to the design of the study (randomized by cluster), regression analyses at individual level that took between-cluster variation into account were performed to assess the intervention effects. For primary efficacy analysis, ED transfers during the first 12 months of follow-up were described and compared between groups using a random-effects logistic regression model, with group as the fixed effect and NH as the random effect. The intervention effect vs control was estimated by the odds ratio and its 95% confidence interval. For participants who did not complete the 12-month follow-up, the primary end point was considered as negative if no ED transfer was reported before study termination.

For the secondary outcomes, random effects logistic regression models were used to test the intervention effect on proportions. The number of times that residents were hospitalized during follow-up was modeled by random-effects negative binomial regression, and intervention effect was measured by rate ratio with its 95% confidence interval. All secondary efficacy analyses were performed at a significance level of 5% without adjustment for multiplicity (see per-protocol and exploratory analyses in eAppendix 7 and eAppendix 8 in Supplement 2).

All analyses were performed using SAS statistical software version 9.4 (SAS Institute Inc).
Significance was set at 2-tailed *P* < .05.

# Results

## Descriptive Results

Eighty-nine NHs agreed to participate in the IDEM study. After cluster randomization, 44 NHs were randomized to the intervention group and 45 to the control group. However, 25 NHs (12 in the intervention group and 13 in the control group) withdrew from the study before the recruitment of the first resident (Figure). A final total of 64 randomized NHs participated in the study, 32 in the intervention group and 32 in the control group (Table 1). Overall, during the 23-month inclusion period, 1428 residents were enrolled in the study (mean [SD] age, 84.7 [8.1] years; 1019 [71.3%] female), 599 in the intervention group and 829 in the control group. In all, 1166 residents (81.7%) were followed for at least 12 months, and the final study visit at 18 months was completed by 1042 residents (73.0%); completion rates were similar between groups. The main reason for early discontinuation was death (318 residents [22.7%]) (Figure). The mean (SD) number of months of follow-up was 15.8 (4.6) in both groups.

Recruitment started on May 1, 2010, and was completed on March 31, 2012. Twenty-seven residents were excluded from the efficacy analysis: 11 in the intervention group (1.8%) and 16 in the control group (1.9%) who were followed up for less than 30 days according to the modified intention-to-treat definition. Baseline characteristics of the 1401 residents included in the modified intention-to-treat analysis (588 in the intervention group and 813 in the control group) are shown in Table 2. The results of the comprehensive geriatric assessment at inclusion and at 18-month follow-up are shown in eTable 1 in Supplement 2.

In the intervention group, the cases of 581 residents (98.8%) were presented at the first MDTM and a conclusion on dementia diagnosis was provided for 574 residents (97.6%): high probability of dementia for 129 residents (22.5%) and suspicion of dementia for 107 residents (18.6%). In 462 cases (79.5%) presented at the first MDTM, the residents' general practitioners (GPs) were informed of the

<figure><img src="image_6.png" /></figure>
conclusion of the first MDTM, and they followed the recommendations for 61.3% of residents. The cases of 401 residents (68.2%) were also discussed in the second MDTM; the GPs of 95.9% of residents were informed of its conclusion, and for 66.6% the recommendations from the second MDTM were followed (Table 3).

Figure. Study Flowchart

<figure><img src="image_6.png" /></figure>

Additional detail is shown in the eFigure in
**Supplement 2.** ITT indicates intention-to-treat; NH,
nursing home; and PP, per-protocol.

<figure><img src="image_7.png" /></figure>
conclusion of the first MDTM, and they followed the recommendations for 61.3% of residents. The cases of 401 residents (68.2%) were also discussed in the second MDTM; the GPs of 95.9% of residents were informed of its conclusion, and for 66.6% the recommendations from the second MDTM were followed (Table 3).

Figure. Study Flowchart

<figure><img src="image_7.png" /></figure>

Additional detail is shown in the eFigure in
**Supplement 2.** ITT indicates intention-to-treat; NH,
nursing home; and PP, per-protocol.

<figure><img src="image_8.png" /></figure>
## Results of Primary Efficacy Outcome

The intervention effects on primary and secondary end point measures in the modified intention-to-treat analyses are presented in **Table 4**. The proportion of residents with at least 1 ED transfer in the 64 NHs during the first 12 months of follow-up showed great variation, from 0% to 58.8% among intervention NHs and from 0% to 39.3% in control NHs. The primary end point, or the proportion of residents with at least 1 ED transfer during the 12-month follow-up, was 16.2% in the intervention group and 12.8% in the control group (odds ratio, 1.32; 95% CI, 0.83-2.09; *P* = .24).

## Results of Analysis of the Secondary End Point

The secondary end point of ED transfer during the entire 18-month follow-up showed no significant differences between groups. Similar results were obtained when adjusting for confounding factors (Table 4). Regarding inappropriate hospitalizations, only hospitalizations for 404 participants for whom a report was available (204 in the intervention group and 200 in the control group) were reviewed by experts. The probability of at least 1 inappropriate hospitalization was significantly higher in the intervention group than in the control group (22.5% vs 7.5%; odds ratio, 3.60 [95% CI, 1.90-6.84]) (Table 4).

The incidence rate of ED transfer during the first 12 months of follow-up for 100 person-years (taking multiple hospitalizations into account) was estimated at 20.06 in the intervention group and 16.27 in the control group (rate ratio, 1.23; 95% CI, 0.78-1.94; *P* = .36) (Table 4). Results of per-protocol and exploratory analyses are given in eAppendix 9 and eAppendix 10 in Supplement 2.

## Discussion

Our findings do not indicate that systematic dementia screening of NH residents through MDTM resulted in a lower rate of ED transfer. To our knowledge, this is the first large-scale randomized clinical trial to test the effectiveness of international recommendations for the diagnosis of Alzheimer disease in NHs.¹ The high rate of new diagnoses of dementia (approximately 41%) among residents who were not previously formally diagnosed in the intervention group confirms the underawareness of dementia in NHs.² However, in spite of these new diagnoses of dementia and the concomitant recognition of various associated geriatric syndromes such as malnutrition, risk of falls, depression, or behavioral disturbances (Table 3) during the MDTM in the intervention group, the overall rate of ED transfers was not lower than in the control group during the first 12 months of follow-up.

Rates of transfer of NH residents to the hospital vary between countries but are approximately 40% per year.¹,¹² Transfers are mainly to the ED, with a high rate of ED transfer for older people with dementia.⁴,¹³,¹⁴ Underrecognition of dementia can result in poor understanding of a resident's

<table><caption>Table 1. Nursing Home Characteristics</caption><thead><tr><th rowspan="2">Characteristic</th><th colspan="3">Mean (SD)</th></tr><tr><th>Intervention (n = 32)</th><th>Control (n = 32)</th><th>Total (N = 64)</th></tr></thead><tbody><tr><td><strong>Stratification factors at inclusion</strong></td><td></td><td></td><td></td></tr><tr><td>Presence of specialized Alzheimer disease care unit, No. (%)</td><td>13 (40.6)</td><td>14 (43.8)</td><td>27 (42.2)</td></tr><tr><td>Participation of nursing home investigator in REHPA geriatric network congresses, No. (%)</td><td>29 (90.6)</td><td>25 (78.1)</td><td>54 (84.4)</td></tr><tr><td>GMP score</td><td>683.4 (137.44)</td><td>707.8 (96.33)</td><td>695.6 (118.37)</td></tr><tr><td><strong>Description of cluster sizes</strong></td><td></td><td></td><td></td></tr><tr><td>No. of residents in the center at inclusion</td><td>81.5 (35.17)</td><td>99.7 (38.78)</td><td>90.6 (37.85)</td></tr><tr><td>No. of residents included by center</td><td>18.7 (8.71)</td><td>25.9 (13.56)</td><td>22.3 (11.87)</td></tr><tr><td>No. of residents included by center in intent-to-treat population</td><td>18.4 (8.62)</td><td>25.4 (12.99)</td><td>21.9 (11.49)</td></tr><tr><td>No. of residents included by center in per-protocol population 1<sup>a</sup></td><td>18.0 (8.43)</td><td>25.3 (12.82)</td><td>21.6 (11.37)</td></tr><tr><td>No. of residents included by center in per-protocol population 2<sup>b</sup></td><td>16.0 (7.33)</td><td>25.3 (12.82)</td><td>21.2 (11.64)</td></tr></tbody></table>

Abbreviations: GMP, GIR moyen pondéré (nursing home dependence score); REHPA, Recherche en Etablissement d'Hébergement pour Personnes Agées (geriatric research network in nursing homes in the Toulouse area).

<figure><img src="image_8.png" /></figure>

<footnote>a Included all participants in the modified intention-to-treat population who met all eligibility criteria; the first multidisciplinary team meeting was held for participants in the intervention group.</footnote>

<footnote>b Included all participants in the modified intention-to-treat population who met all eligibility criteria; the first and second multidisciplinary team meetings were held for participants in the intervention group.</footnote>
## Results of Primary Efficacy Outcome

The intervention effects on primary and secondary end point measures in the modified intention-to-treat analyses are presented in **Table 4**. The proportion of residents with at least 1 ED transfer in the 64 NHs during the first 12 months of follow-up showed great variation, from 0% to 58.8% among intervention NHs and from 0% to 39.3% in control NHs. The primary end point, or the proportion of residents with at least 1 ED transfer during the 12-month follow-up, was 16.2% in the intervention group and 12.8% in the control group (odds ratio, 1.32; 95% CI, 0.83-2.09; *P* = .24).

## Results of Analysis of the Secondary End Point

The secondary end point of ED transfer during the entire 18-month follow-up showed no significant differences between groups. Similar results were obtained when adjusting for confounding factors (Table 4). Regarding inappropriate hospitalizations, only hospitalizations for 404 participants for whom a report was available (204 in the intervention group and 200 in the control group) were reviewed by experts. The probability of at least 1 inappropriate hospitalization was significantly higher in the intervention group than in the control group (22.5% vs 7.5%; odds ratio, 3.60 [95% CI, 1.90-6.84]) (Table 4).

The incidence rate of ED transfer during the first 12 months of follow-up for 100 person-years (taking multiple hospitalizations into account) was estimated at 20.06 in the intervention group and 16.27 in the control group (rate ratio, 1.23; 95% CI, 0.78-1.94; *P* = .36) (Table 4). Results of per-protocol and exploratory analyses are given in eAppendix 9 and eAppendix 10 in Supplement 2.

## Discussion

Our findings do not indicate that systematic dementia screening of NH residents through MDTM resulted in a lower rate of ED transfer. To our knowledge, this is the first large-scale randomized clinical trial to test the effectiveness of international recommendations for the diagnosis of Alzheimer disease in NHs.¹ The high rate of new diagnoses of dementia (approximately 41%) among residents who were not previously formally diagnosed in the intervention group confirms the underawareness of dementia in NHs.² However, in spite of these new diagnoses of dementia and the concomitant recognition of various associated geriatric syndromes such as malnutrition, risk of falls, depression, or behavioral disturbances (Table 3) during the MDTM in the intervention group, the overall rate of ED transfers was not lower than in the control group during the first 12 months of follow-up.

Rates of transfer of NH residents to the hospital vary between countries but are approximately 40% per year.¹,¹² Transfers are mainly to the ED, with a high rate of ED transfer for older people with dementia.⁴,¹³,¹⁴ Underrecognition of dementia can result in poor understanding of a resident's

<table><caption>Table 1. Nursing Home Characteristics</caption><thead><tr><th rowspan="2">Characteristic</th><th colspan="3">Mean (SD)</th></tr><tr><th>Intervention (n = 32)</th><th>Control (n = 32)</th><th>Total (N = 64)</th></tr></thead><tbody><tr><td><strong>Stratification factors at inclusion</strong></td><td></td><td></td><td></td></tr><tr><td>Presence of specialized Alzheimer disease care unit, No. (%)</td><td>13 (40.6)</td><td>14 (43.8)</td><td>27 (42.2)</td></tr><tr><td>Participation of nursing home investigator in REHPA geriatric network congresses, No. (%)</td><td>29 (90.6)</td><td>25 (78.1)</td><td>54 (84.4)</td></tr><tr><td>GMP score</td><td>683.4 (137.44)</td><td>707.8 (96.33)</td><td>695.6 (118.37)</td></tr><tr><td><strong>Description of cluster sizes</strong></td><td></td><td></td><td></td></tr><tr><td>No. of residents in the center at inclusion</td><td>81.5 (35.17)</td><td>99.7 (38.78)</td><td>90.6 (37.85)</td></tr><tr><td>No. of residents included by center</td><td>18.7 (8.71)</td><td>25.9 (13.56)</td><td>22.3 (11.87)</td></tr><tr><td>No. of residents included by center in intent-to-treat population</td><td>18.4 (8.62)</td><td>25.4 (12.99)</td><td>21.9 (11.49)</td></tr><tr><td>No. of residents included by center in per-protocol population 1<sup>a</sup></td><td>18.0 (8.43)</td><td>25.3 (12.82)</td><td>21.6 (11.37)</td></tr><tr><td>No. of residents included by center in per-protocol population 2<sup>b</sup></td><td>16.0 (7.33)</td><td>25.3 (12.82)</td><td>21.2 (11.64)</td></tr></tbody></table>

Abbreviations: GMP, GIR moyen pondéré (nursing home dependence score); REHPA, Recherche en Etablissement d'Hébergement pour Personnes Agées (geriatric research network in nursing homes in the Toulouse area).

<figure><img src="image_9.png" /></figure>

<footnote>a Included all participants in the modified intention-to-treat population who met all eligibility criteria; the first multidisciplinary team meeting was held for participants in the intervention group.</footnote>

<footnote>b Included all participants in the modified intention-to-treat population who met all eligibility criteria; the first and second multidisciplinary team meetings were held for participants in the intervention group.</footnote>
<table><caption>Table 2. Participant Characteristics at Inclusion (Modified Intention-to-Treat Population)</caption><thead><tr><th rowspan="2">Characteristic</th><th colspan="3">No. (%)</th></tr><tr><th>Intervention (n = 588)</th><th>Control (n = 813)</th><th>All (N = 1401)</th></tr></thead><tbody><tr><td><strong>Demographic</strong></td><td></td><td></td><td></td></tr><tr><td>Age, mean (SD), y</td><td>85.0 (7.95)</td><td>84.4 (8.19)</td><td>84.7 (8.09)</td></tr><tr><td>Female</td><td>422 (71.8)</td><td>582 (71.6)</td><td>1004 (71.7)</td></tr><tr><td>Marital status</td><td></td><td></td><td></td></tr><tr><td>Married</td><td>37 (6.3)</td><td>69 (8.6)</td><td>106 (7.6)</td></tr><tr><td>Widowed</td><td>371 (63.2)</td><td>476 (59.3)</td><td>847 (60.9)</td></tr><tr><td>Single</td><td>133 (22.7)</td><td>196 (24.4)</td><td>329 (23.7)</td></tr><tr><td>Divorced</td><td>46 (7.8)</td><td>62 (7.7)</td><td>108 (7.8)</td></tr><tr><td>Education</td><td></td><td></td><td></td></tr><tr><td>No education</td><td>26 (4.4)</td><td>52 (6.5)</td><td>78 (5.6)</td></tr><tr><td>Primary school</td><td>173 (29.5)</td><td>225 (27.9)</td><td>398 (28.6)</td></tr><tr><td>Primary school certificate</td><td>208 (35.4)</td><td>256 (31.8)</td><td>464 (33.3)</td></tr><tr><td>Elementary school or vocational diploma</td><td>105 (17.9)</td><td>158 (19.6)</td><td>263 (18.9)</td></tr><tr><td>A levels or higher diploma</td><td>75 (12.8)</td><td>115 (14.3)</td><td>190 (13.6)</td></tr><tr><td>French as native language</td><td>553 (94.0)</td><td>757 (93.1)</td><td>1310 (93.5)</td></tr><tr><td>Length of stay in the nursing home at inclusion, mean (SD), mo</td><td>47.7 (68.95)</td><td>56.5 (75.88)</td><td>52.8 (73.18)</td></tr><tr><td><strong>Medical history</strong></td><td></td><td></td><td></td></tr><tr><td>Charlson Comorbidity Index score, mean (SD)</td><td>2.0 (1.84)</td><td>2.0 (1.99)</td><td>2.0 (1.92)</td></tr><tr><td>Current smoker</td><td>32 (5.4)</td><td>37 (4.6)</td><td>69 (4.9)</td></tr><tr><td>Alcohol consumption</td><td>188 (32.0)</td><td>227 (27.9)</td><td>415 (29.6)</td></tr><tr><td>Vascular risk factors</td><td>483 (82.1)</td><td>676 (83.3)</td><td>1159 (82.8)</td></tr><tr><td>History of psychological disorders</td><td>326 (55.5)</td><td>527 (64.9)</td><td>853 (61.0)</td></tr><tr><td>History of fracture</td><td>242 (41.2)</td><td>366 (45.1)</td><td>608 (43.5)</td></tr><tr><td>Progressive cognitive decline</td><td>123 (20.9)</td><td>167 (20.6)</td><td>290 (20.7)</td></tr><tr><td>Mini-Mental State Examination carried out in the past 6 mo</td><td>275 (46.9)</td><td>474 (58.4)</td><td>749 (53.6)</td></tr><tr><td>Mini-Mental State Examination score in the past 6 mo, mean (SD)</td><td>22.1 (5.29)</td><td>22.8 (5.22)</td><td>22.5 (5.25)</td></tr><tr><td>Family history of dementia</td><td>29 (4.9)</td><td>28 (3.4)</td><td>57 (4.1)</td></tr><tr><td>≥1 Hospital admission in past 3 mo</td><td>77 (13.1)</td><td>95 (11.7)</td><td>172 (12.3)</td></tr><tr><td>≥1 Emergency department admission in past 3 mo</td><td>48 (8.2)</td><td>48 (5.9)</td><td>96 (6.9)</td></tr><tr><td><strong>Medication use at inclusion</strong></td><td></td><td></td><td></td></tr><tr><td>Neuroleptics</td><td>86 (14.6)</td><td>143 (17.6)</td><td>229 (16.3)</td></tr><tr><td>Benzodiazepines</td><td>310 (52.7)</td><td>441 (54.2)</td><td>751 (53.6)</td></tr><tr><td>Anxiolytics</td><td>220 (37.4)</td><td>353 (43.4)</td><td>573 (40.9)</td></tr><tr><td>Antidepressants</td><td>238 (40.5)</td><td>382 (47.0)</td><td>620 (44.3)</td></tr><tr><td>Hypnotics</td><td>198 (33.7)</td><td>286 (35.2)</td><td>484 (34.5)</td></tr><tr><td>Thymoregulators</td><td>30 (5.1)</td><td>62 (7.6)</td><td>92 (6.6)</td></tr><tr><td>Psychostimulants</td><td>238 (40.5)</td><td>384 (47.2)</td><td>622 (44.4)</td></tr><tr><td>Antiepileptics</td><td>84 (14.3)</td><td>125 (15.4)</td><td>209 (14.9)</td></tr><tr><td>Vitamin D</td><td>27 (4.6)</td><td>37 (4.6)</td><td>64 (4.6)</td></tr><tr><td>Vitamin K antagonists</td><td>28 (4.8)</td><td>25 (3.1)</td><td>53 (3.8)</td></tr><tr><td>Platelet aggregation inhibitors</td><td>214 (36.4)</td><td>293 (36.0)</td><td>507 (36.2)</td></tr><tr><td>Analgesics</td><td>277 (47.1)</td><td>369 (45.4)</td><td>646 (46.1)</td></tr><tr><td>Proton pump inhibitors</td><td>236 (40.1)</td><td>332 (40.8)</td><td>568 (40.5)</td></tr><tr><td><strong>Nonmedicinal treatments</strong></td><td></td><td></td><td></td></tr><tr><td>Physiotherapy</td><td>245 (41.7)</td><td>261 (32.1)</td><td>506 (36.1)</td></tr><tr><td>Ergotherapy</td><td>46 (7.8)</td><td>44 (5.4)</td><td>90 (6.4)</td></tr><tr><td>Psychomotricity</td><td>37 (6.3)</td><td>38 (4.7)</td><td>75 (5.4)</td></tr><tr><td>Psychological follow-up</td><td>146 (24.8)</td><td>224 (27.6)</td><td>370 (26.4)</td></tr><tr><td>Dietetic follow-up</td><td>91 (15.5)</td><td>112 (13.8)</td><td>203 (14.5)</td></tr><tr><td>Speech therapy</td><td>10 (1.7)</td><td>5 (0.6)</td><td>15 (1.1)</td></tr><tr><td>Other nonmedicinal treatment</td><td>30 (5.1)</td><td>62 (7.6)</td><td>92 (6.6)</td></tr></tbody></table>

<figure><img src="image_9.png" /></figure>
<table><caption>Table 2. Participant Characteristics at Inclusion (Modified Intention-to-Treat Population)</caption><thead><tr><th rowspan="2">Characteristic</th><th colspan="3">No. (%)</th></tr><tr><th>Intervention (n = 588)</th><th>Control (n = 813)</th><th>All (N = 1401)</th></tr></thead><tbody><tr><td><strong>Demographic</strong></td><td></td><td></td><td></td></tr><tr><td>Age, mean (SD), y</td><td>85.0 (7.95)</td><td>84.4 (8.19)</td><td>84.7 (8.09)</td></tr><tr><td>Female</td><td>422 (71.8)</td><td>582 (71.6)</td><td>1004 (71.7)</td></tr><tr><td>Marital status</td><td></td><td></td><td></td></tr><tr><td>Married</td><td>37 (6.3)</td><td>69 (8.6)</td><td>106 (7.6)</td></tr><tr><td>Widowed</td><td>371 (63.2)</td><td>476 (59.3)</td><td>847 (60.9)</td></tr><tr><td>Single</td><td>133 (22.7)</td><td>196 (24.4)</td><td>329 (23.7)</td></tr><tr><td>Divorced</td><td>46 (7.8)</td><td>62 (7.7)</td><td>108 (7.8)</td></tr><tr><td>Education</td><td></td><td></td><td></td></tr><tr><td>No education</td><td>26 (4.4)</td><td>52 (6.5)</td><td>78 (5.6)</td></tr><tr><td>Primary school</td><td>173 (29.5)</td><td>225 (27.9)</td><td>398 (28.6)</td></tr><tr><td>Primary school certificate</td><td>208 (35.4)</td><td>256 (31.8)</td><td>464 (33.3)</td></tr><tr><td>Elementary school or vocational diploma</td><td>105 (17.9)</td><td>158 (19.6)</td><td>263 (18.9)</td></tr><tr><td>A levels or higher diploma</td><td>75 (12.8)</td><td>115 (14.3)</td><td>190 (13.6)</td></tr><tr><td>French as native language</td><td>553 (94.0)</td><td>757 (93.1)</td><td>1310 (93.5)</td></tr><tr><td>Length of stay in the nursing home at inclusion, mean (SD), mo</td><td>47.7 (68.95)</td><td>56.5 (75.88)</td><td>52.8 (73.18)</td></tr><tr><td><strong>Medical history</strong></td><td></td><td></td><td></td></tr><tr><td>Charlson Comorbidity Index score, mean (SD)</td><td>2.0 (1.84)</td><td>2.0 (1.99)</td><td>2.0 (1.92)</td></tr><tr><td>Current smoker</td><td>32 (5.4)</td><td>37 (4.6)</td><td>69 (4.9)</td></tr><tr><td>Alcohol consumption</td><td>188 (32.0)</td><td>227 (27.9)</td><td>415 (29.6)</td></tr><tr><td>Vascular risk factors</td><td>483 (82.1)</td><td>676 (83.3)</td><td>1159 (82.8)</td></tr><tr><td>History of psychological disorders</td><td>326 (55.5)</td><td>527 (64.9)</td><td>853 (61.0)</td></tr><tr><td>History of fracture</td><td>242 (41.2)</td><td>366 (45.1)</td><td>608 (43.5)</td></tr><tr><td>Progressive cognitive decline</td><td>123 (20.9)</td><td>167 (20.6)</td><td>290 (20.7)</td></tr><tr><td>Mini-Mental State Examination carried out in the past 6 mo</td><td>275 (46.9)</td><td>474 (58.4)</td><td>749 (53.6)</td></tr><tr><td>Mini-Mental State Examination score in the past 6 mo, mean (SD)</td><td>22.1 (5.29)</td><td>22.8 (5.22)</td><td>22.5 (5.25)</td></tr><tr><td>Family history of dementia</td><td>29 (4.9)</td><td>28 (3.4)</td><td>57 (4.1)</td></tr><tr><td>≥1 Hospital admission in past 3 mo</td><td>77 (13.1)</td><td>95 (11.7)</td><td>172 (12.3)</td></tr><tr><td>≥1 Emergency department admission in past 3 mo</td><td>48 (8.2)</td><td>48 (5.9)</td><td>96 (6.9)</td></tr><tr><td><strong>Medication use at inclusion</strong></td><td></td><td></td><td></td></tr><tr><td>Neuroleptics</td><td>86 (14.6)</td><td>143 (17.6)</td><td>229 (16.3)</td></tr><tr><td>Benzodiazepines</td><td>310 (52.7)</td><td>441 (54.2)</td><td>751 (53.6)</td></tr><tr><td>Anxiolytics</td><td>220 (37.4)</td><td>353 (43.4)</td><td>573 (40.9)</td></tr><tr><td>Antidepressants</td><td>238 (40.5)</td><td>382 (47.0)</td><td>620 (44.3)</td></tr><tr><td>Hypnotics</td><td>198 (33.7)</td><td>286 (35.2)</td><td>484 (34.5)</td></tr><tr><td>Thymoregulators</td><td>30 (5.1)</td><td>62 (7.6)</td><td>92 (6.6)</td></tr><tr><td>Psychostimulants</td><td>238 (40.5)</td><td>384 (47.2)</td><td>622 (44.4)</td></tr><tr><td>Antiepileptics</td><td>84 (14.3)</td><td>125 (15.4)</td><td>209 (14.9)</td></tr><tr><td>Vitamin D</td><td>27 (4.6)</td><td>37 (4.6)</td><td>64 (4.6)</td></tr><tr><td>Vitamin K antagonists</td><td>28 (4.8)</td><td>25 (3.1)</td><td>53 (3.8)</td></tr><tr><td>Platelet aggregation inhibitors</td><td>214 (36.4)</td><td>293 (36.0)</td><td>507 (36.2)</td></tr><tr><td>Analgesics</td><td>277 (47.1)</td><td>369 (45.4)</td><td>646 (46.1)</td></tr><tr><td>Proton pump inhibitors</td><td>236 (40.1)</td><td>332 (40.8)</td><td>568 (40.5)</td></tr><tr><td><strong>Nonmedicinal treatments</strong></td><td></td><td></td><td></td></tr><tr><td>Physiotherapy</td><td>245 (41.7)</td><td>261 (32.1)</td><td>506 (36.1)</td></tr><tr><td>Ergotherapy</td><td>46 (7.8)</td><td>44 (5.4)</td><td>90 (6.4)</td></tr><tr><td>Psychomotricity</td><td>37 (6.3)</td><td>38 (4.7)</td><td>75 (5.4)</td></tr><tr><td>Psychological follow-up</td><td>146 (24.8)</td><td>224 (27.6)</td><td>370 (26.4)</td></tr><tr><td>Dietetic follow-up</td><td>91 (15.5)</td><td>112 (13.8)</td><td>203 (14.5)</td></tr><tr><td>Speech therapy</td><td>10 (1.7)</td><td>5 (0.6)</td><td>15 (1.1)</td></tr><tr><td>Other nonmedicinal treatment</td><td>30 (5.1)</td><td>62 (7.6)</td><td>92 (6.6)</td></tr></tbody></table>

<figure><img src="image_10.png" /></figure>
<table><caption>Table 3. First and Second MDTMs in Modified Intention-to-Treat Population, Intervention Group</caption><thead><tr><th>Characteristic</th><th>No./Total No. (%) (N = 588)<sup>a</sup></th></tr></thead><tbody><tr><td><strong>First MDTM</strong></td><td></td></tr><tr><td>Residents whose case was studied during the first MDTM</td><td>581/588 (98.8)</td></tr><tr><td>Time spent on each case, mean (SD), min</td><td>15.8 (7.0)</td></tr><tr><td>No. of experts participating in the first MDTM, mean (SD)</td><td>4.2 (1.6)</td></tr><tr><td>Conclusion on dementia diagnosis</td><td></td></tr><tr><td>High probability of dementia</td><td>129/574 (22.5)</td></tr><tr><td>Absence of dementia with normal cognitive test results</td><td>207/574 (36.1)</td></tr><tr><td>Absence of dementia with abnormal cognitive test results</td><td>103/574 (17.9)</td></tr><tr><td>Suspicion of dementia</td><td>107/574 (18.6)</td></tr><tr><td>Lack of data or incomplete medical file</td><td>28/574 (4.9)</td></tr><tr><td>Symptoms present at inclusion visit</td><td>581/581 (100)</td></tr><tr><td>Delirium syndrome</td><td>8/581 (1.4)</td></tr><tr><td>Depressive syndrome</td><td>243/581 (41.8)</td></tr><tr><td>Malnutrition</td><td>141/581 (24.3)</td></tr><tr><td>High risk of fracture</td><td>272/581 (46.8)</td></tr><tr><td>Behavioral disturbances</td><td>153/581 (26.3)</td></tr><tr><td>Care plan proposed at the first MDTM</td><td>580/581 (99.8)</td></tr><tr><td>Proposal for further examinations</td><td>308/580 (53.1)</td></tr><tr><td>Laboratory tests</td><td>207/308 (67.2)</td></tr><tr><td>Cerebral computed tomography</td><td>101/308 (32.8)</td></tr><tr><td>Cerebral magnetic resonance imaging</td><td>27/308 (8.8)</td></tr><tr><td>Additional psychometric evaluation</td><td>113/308 (36.7)</td></tr><tr><td>Therapeutic proposal</td><td>470/580 (81.0)</td></tr><tr><td>Discussion of value of specific treatment of Alzheimer disease</td><td>64/470 (13.6)</td></tr><tr><td>Discontinuation of a psychotropic treatment</td><td>115/470 (24.5)</td></tr><tr><td>Introduction of a psychotropic treatment</td><td>8/470 (16.6)</td></tr><tr><td>Other changes in drug treatment</td><td>159/470 (33.8)</td></tr><tr><td>Proposal for nondrug treatment</td><td>271/470 (57.7)</td></tr><tr><td>Proposal of general preventive measures</td><td>355/470 (75.5)</td></tr><tr><td>Need for immediate hospitalization</td><td>29/580 (5.0)</td></tr><tr><td>Need for move to another nursing home</td><td>3/580 (0.5)</td></tr><tr><td>Resident's GP informed of MDTM conclusions</td><td>462/581 (79.5)</td></tr><tr><td>First MDTM recommendations followed by resident's GP</td><td>273/445 (61.3)</td></tr><tr><td><strong>Second MDTM</strong></td><td></td></tr><tr><td>Residents whose case was studied during the second MDTM</td><td>401/588 (68.2)</td></tr><tr><td>Appearance of new developments since the first MDTM</td><td>210/401 (52.4)</td></tr><tr><td>Care plan proposed at the second MDTM</td><td>400/401 (99.8)</td></tr><tr><td>Proposal for further examinations</td><td>105/400 (26.3)</td></tr><tr><td>New therapeutic proposal</td><td>161/400 (40.3)</td></tr><tr><td>Discussion of the value of a specific treatment of Alzheimer disease</td><td>23/161 (14.3)</td></tr><tr><td>Discontinuation of a psychotropic treatment</td><td>64/161 (39.8)</td></tr><tr><td>Introduction of a psychotropic treatment</td><td>25/161 (15.5)</td></tr><tr><td>Other drug modifications</td><td>112/161 (69.6)</td></tr><tr><td>Specific recommendations to limit the need for emergency department</td><td>91/400 (22.8)</td></tr><tr><td>Need for regular monitoring by the memory clinic</td><td>21/91 (23.1)</td></tr><tr><td>Need for an outpatient specialist visit</td><td>80/91 (87.9)</td></tr><tr><td>Need for immediate hospitalization</td><td>6/91 (6.6)</td></tr><tr><td>Need for move to another nursing home</td><td>2/91 (2.2)</td></tr><tr><td>Resident's GP informed of second MDTM conclusions</td><td>351/366 (95.9)</td></tr><tr><td>Second MDTM recommendations followed by resident's GP</td><td>235/353 (66.6)</td></tr><tr><td>First and second MDTM recommendations followed by resident's GP</td><td>147/371 (39.6)</td></tr></tbody></table>

Abbreviations: GP, general practitioner; MDTM, multidisciplinary team meeting.

<figure><img src="image_10.png" /></figure>

<footnote>a Number of participants whose data were available.</footnote>
<table><caption>Table 3. First and Second MDTMs in Modified Intention-to-Treat Population, Intervention Group</caption><thead><tr><th>Characteristic</th><th>No./Total No. (%) (N = 588)<sup>a</sup></th></tr></thead><tbody><tr><td><strong>First MDTM</strong></td><td></td></tr><tr><td>Residents whose case was studied during the first MDTM</td><td>581/588 (98.8)</td></tr><tr><td>Time spent on each case, mean (SD), min</td><td>15.8 (7.0)</td></tr><tr><td>No. of experts participating in the first MDTM, mean (SD)</td><td>4.2 (1.6)</td></tr><tr><td>Conclusion on dementia diagnosis</td><td></td></tr><tr><td>High probability of dementia</td><td>129/574 (22.5)</td></tr><tr><td>Absence of dementia with normal cognitive test results</td><td>207/574 (36.1)</td></tr><tr><td>Absence of dementia with abnormal cognitive test results</td><td>103/574 (17.9)</td></tr><tr><td>Suspicion of dementia</td><td>107/574 (18.6)</td></tr><tr><td>Lack of data or incomplete medical file</td><td>28/574 (4.9)</td></tr><tr><td>Symptoms present at inclusion visit</td><td>581/581 (100)</td></tr><tr><td>Delirium syndrome</td><td>8/581 (1.4)</td></tr><tr><td>Depressive syndrome</td><td>243/581 (41.8)</td></tr><tr><td>Malnutrition</td><td>141/581 (24.3)</td></tr><tr><td>High risk of fracture</td><td>272/581 (46.8)</td></tr><tr><td>Behavioral disturbances</td><td>153/581 (26.3)</td></tr><tr><td>Care plan proposed at the first MDTM</td><td>580/581 (99.8)</td></tr><tr><td>Proposal for further examinations</td><td>308/580 (53.1)</td></tr><tr><td>Laboratory tests</td><td>207/308 (67.2)</td></tr><tr><td>Cerebral computed tomography</td><td>101/308 (32.8)</td></tr><tr><td>Cerebral magnetic resonance imaging</td><td>27/308 (8.8)</td></tr><tr><td>Additional psychometric evaluation</td><td>113/308 (36.7)</td></tr><tr><td>Therapeutic proposal</td><td>470/580 (81.0)</td></tr><tr><td>Discussion of value of specific treatment of Alzheimer disease</td><td>64/470 (13.6)</td></tr><tr><td>Discontinuation of a psychotropic treatment</td><td>115/470 (24.5)</td></tr><tr><td>Introduction of a psychotropic treatment</td><td>8/470 (16.6)</td></tr><tr><td>Other changes in drug treatment</td><td>159/470 (33.8)</td></tr><tr><td>Proposal for nondrug treatment</td><td>271/470 (57.7)</td></tr><tr><td>Proposal of general preventive measures</td><td>355/470 (75.5)</td></tr><tr><td>Need for immediate hospitalization</td><td>29/580 (5.0)</td></tr><tr><td>Need for move to another nursing home</td><td>3/580 (0.5)</td></tr><tr><td>Resident's GP informed of MDTM conclusions</td><td>462/581 (79.5)</td></tr><tr><td>First MDTM recommendations followed by resident's GP</td><td>273/445 (61.3)</td></tr><tr><td><strong>Second MDTM</strong></td><td></td></tr><tr><td>Residents whose case was studied during the second MDTM</td><td>401/588 (68.2)</td></tr><tr><td>Appearance of new developments since the first MDTM</td><td>210/401 (52.4)</td></tr><tr><td>Care plan proposed at the second MDTM</td><td>400/401 (99.8)</td></tr><tr><td>Proposal for further examinations</td><td>105/400 (26.3)</td></tr><tr><td>New therapeutic proposal</td><td>161/400 (40.3)</td></tr><tr><td>Discussion of the value of a specific treatment of Alzheimer disease</td><td>23/161 (14.3)</td></tr><tr><td>Discontinuation of a psychotropic treatment</td><td>64/161 (39.8)</td></tr><tr><td>Introduction of a psychotropic treatment</td><td>25/161 (15.5)</td></tr><tr><td>Other drug modifications</td><td>112/161 (69.6)</td></tr><tr><td>Specific recommendations to limit the need for emergency department</td><td>91/400 (22.8)</td></tr><tr><td>Need for regular monitoring by the memory clinic</td><td>21/91 (23.1)</td></tr><tr><td>Need for an outpatient specialist visit</td><td>80/91 (87.9)</td></tr><tr><td>Need for immediate hospitalization</td><td>6/91 (6.6)</td></tr><tr><td>Need for move to another nursing home</td><td>2/91 (2.2)</td></tr><tr><td>Resident's GP informed of second MDTM conclusions</td><td>351/366 (95.9)</td></tr><tr><td>Second MDTM recommendations followed by resident's GP</td><td>235/353 (66.6)</td></tr><tr><td>First and second MDTM recommendations followed by resident's GP</td><td>147/371 (39.6)</td></tr></tbody></table>

Abbreviations: GP, general practitioner; MDTM, multidisciplinary team meeting.

<figure><img src="image_11.png" /></figure>

<footnote>a Number of participants whose data were available.</footnote>
behavior and inappropriate therapy, ultimately leading to an inappropriate care plan. When residents with dementia are hospitalized, they are generally exposed to iatrogenic events and delirium¹⁵ and have a longer hospital stay and greater functional decline than elderly people with similar health conditions but without dementia.¹,¹²,¹⁶ On the other hand, previous research has indicated that dementia plays a moderating role in the associations between acute diseases and ED transfers.¹⁷ In our study, the mean proportion of participants with at least 1 ED transfer during the first 12 months of follow-up in the overall population was high (around 14%). It was higher, but not significantly so, in the intervention group than in the control group, but ED transfer rate varied greatly between NHs (Table 4; eTable 2 in Supplement 2), suggesting large disparity of practices among NHs. The intervention was mainly focused on dementia screening rather than specifically on reducing ED transfers (or the prevention of acute health conditions) and was probably too weak to set a downward trend in the routine practice of transfers and the habits of each NH staff.

These results must be analyzed with caution. A reduced ED transfer rate was expected in residents newly diagnosed with dementia (approximately 41% of the intervention group diagnosed with highly probable or suspected dementia), but our intervention may have also resulted in an increased ED transfer rate among residents newly confirmed without dementia (54% of the intervention group) (Table 3). Awareness that a resident does not have dementia may in fact change the attitude of the NH staff and encourage a maximal approach to care. We speculate that our neutral results may be explained by a lower hospitalization rate of residents with a highly probable or suspected diagnosis of dementia, balanced by a higher hospitalization rate of residents with confirmed exclusion of diagnosis of dementia. This hypothesis may explain our counterintuitive results and support better quality of care. However, the supplementary analyses tend to refute this hypothesis (eTable 3 in Supplement 2). In fact, subgroup analysis according to dementia status found

<table><caption>Table 4. Assessment of Intervention Effect on Primary and Secondary End Points in Modified Intention-to-Treat Population, Per-protocol Population 1, and Per-protocol Population 2</caption><thead><tr><th rowspan="2">End Point</th><th colspan="2">No./Total No. (%)</th><th rowspan="2">Ratio (95% CI)</th><th rowspan="2">P Value</th></tr><tr><th>Intervention</th><th>Control</th></tr></thead><tbody><tr><td>Modified intention-to-treat population, No. (n = 1401)</td><td>588</td><td>813</td><td></td><td></td></tr><tr><td>Primary end point: ED transfer during 12-mo follow-up<sup>a</sup></td><td>95 (16.2)</td><td>104 (12.8)</td><td>1.32 (0.83-2.09)<sup>b</sup></td><td>.24</td></tr><tr><td>Incidence rate of ED transfer during 12-mo follow-up for 100 person-years (95% CI)</td><td>20.06 (14.34-28.06)</td><td>16.27 (11.77-22.49)</td><td>1.23 (0.78-1.94)<sup>c</sup></td><td>.36</td></tr><tr><td>ED transfer during 18-mo follow-up</td><td>118 (20.1)</td><td>145 (17.8)</td><td>1.16 (0.71 to 1.91)<sup>b</sup></td><td>.54</td></tr><tr><td>Incidence rate of ED transfer during 18-mo follow-up for 100 person-years (95% CI)</td><td>18.97 (13.55-26.55)</td><td>16.87 (12.26-23.23)</td><td>1.12 (0.71-1.77)<sup>c</sup></td><td>.61</td></tr><tr><td>ED transfer judged inappropriate by experts during 18-mo follow-up (n = 404)</td><td>46/204 (22.5)</td><td>15/200 (7.5)</td><td>3.60 (1.90-6.84)<sup>b</sup></td><td>&lt;.001</td></tr><tr><td>Incidence rate of ED transfer whatever the hospital unit during 18-mo follow-up in person-years (95% CI)</td><td>73.56 (58.95-91.79)</td><td>74.43 (60.59-91.43)</td><td>0.99 (0.73-1.33)<sup>c</sup></td><td>.93</td></tr><tr><td>Subgroup analyses: ED transfer during 12-mo follow-up in the subgroups</td><td></td><td></td><td></td><td></td></tr><tr><td>NHs with Alzheimer disease unit (n = 558)</td><td>28/233 (12.0)</td><td>52/325 (16.0)</td><td>0.75 (0.41-1.41)<sup>b</sup></td><td>.37</td></tr><tr><td>NHs without Alzheimer disease unit (n = 843)</td><td>67/355 (18.9)</td><td>52/488 (10.7)</td><td>1.88 (1.01-3.52)<sup>b</sup></td><td>.04</td></tr><tr><td>Public NHs (n = 781)</td><td>59/402 (14.7)</td><td>55/379 (14.5)</td><td>1.00 (0.53-1.90)<sup>b</sup></td><td>.99</td></tr><tr><td>Private NHs (n = 620)</td><td>36/186 (19.4)</td><td>49/434 (11.3)</td><td>1.85 (0.97-3.55)<sup>b</sup></td><td>.06</td></tr><tr><td>Per-protocol population 1, No. (n = 1384)</td><td>576</td><td>808</td><td></td><td></td></tr><tr><td>ED transfer during 12-mo follow-up</td><td>94 (16.3)</td><td>103 (12.7)</td><td>1.34 (0.84-2.13)<sup>b</sup></td><td>.21</td></tr><tr><td>Incidence rate of ED transfer during 12-mo follow-up for 100 person-years (95% CI)</td><td>20.14 (14.38-28.22)</td><td>16.27 (11.76-22.52)</td><td>1.24 (0.79-1.95)<sup>c</sup></td><td>.35</td></tr><tr><td>ED transfer during 18-mo follow-up</td><td>116 (20.1)</td><td>144 (17.8)</td><td>1.17 (0.72-1.91)<sup>b</sup></td><td>.52</td></tr><tr><td>Incidence rate of ED transfer during 18-mo follow-up for 100 person-years (95% CI)</td><td>19.04 (13.61-26.65)</td><td>16.95 (12.32-23.32)</td><td>1.12 (0.71-1.77)<sup>c</sup></td><td>.61</td></tr><tr><td>Per-protocol population 2, No. (n = 1208)</td><td>400</td><td>808</td><td></td><td></td></tr><tr><td>ED transfer during 18-mo follow-up</td><td>71 (17.8)</td><td>144 (17.8)</td><td>0.99 (0.57-1.73)<sup>b</sup></td><td>.97</td></tr><tr><td>Incidence rate of ED transfer during 18-mo follow-up for 100 person-years (95% CI)</td><td>14.29 (9.41-21.70)</td><td>16.65 (11.84-23.41)</td><td>0.86 (0.51-1.46)<sup>c</sup></td><td>.57</td></tr></tbody></table>

Abbreviations: ED, emergency department; NH, nursing home.

a The intracluster correlation coefficient indicates the similarity of measurements of participants from the same cluster with those from different clusters and was estimated at 0.1129 for the primary end point.

b Odds ratio for intervention vs control.

c Rate ratio for intervention vs control.

<figure><img src="image_11.png" /></figure>
behavior and inappropriate therapy, ultimately leading to an inappropriate care plan. When residents with dementia are hospitalized, they are generally exposed to iatrogenic events and delirium¹⁵ and have a longer hospital stay and greater functional decline than elderly people with similar health conditions but without dementia.¹,¹²,¹⁶ On the other hand, previous research has indicated that dementia plays a moderating role in the associations between acute diseases and ED transfers.¹⁷ In our study, the mean proportion of participants with at least 1 ED transfer during the first 12 months of follow-up in the overall population was high (around 14%). It was higher, but not significantly so, in the intervention group than in the control group, but ED transfer rate varied greatly between NHs (Table 4; eTable 2 in Supplement 2), suggesting large disparity of practices among NHs. The intervention was mainly focused on dementia screening rather than specifically on reducing ED transfers (or the prevention of acute health conditions) and was probably too weak to set a downward trend in the routine practice of transfers and the habits of each NH staff.

These results must be analyzed with caution. A reduced ED transfer rate was expected in residents newly diagnosed with dementia (approximately 41% of the intervention group diagnosed with highly probable or suspected dementia), but our intervention may have also resulted in an increased ED transfer rate among residents newly confirmed without dementia (54% of the intervention group) (Table 3). Awareness that a resident does not have dementia may in fact change the attitude of the NH staff and encourage a maximal approach to care. We speculate that our neutral results may be explained by a lower hospitalization rate of residents with a highly probable or suspected diagnosis of dementia, balanced by a higher hospitalization rate of residents with confirmed exclusion of diagnosis of dementia. This hypothesis may explain our counterintuitive results and support better quality of care. However, the supplementary analyses tend to refute this hypothesis (eTable 3 in Supplement 2). In fact, subgroup analysis according to dementia status found

<table><caption>Table 4. Assessment of Intervention Effect on Primary and Secondary End Points in Modified Intention-to-Treat Population, Per-protocol Population 1, and Per-protocol Population 2</caption><thead><tr><th rowspan="2">End Point</th><th colspan="2">No./Total No. (%)</th><th rowspan="2">Ratio (95% CI)</th><th rowspan="2">P Value</th></tr><tr><th>Intervention</th><th>Control</th></tr></thead><tbody><tr><td>Modified intention-to-treat population, No. (n = 1401)</td><td>588</td><td>813</td><td></td><td></td></tr><tr><td>Primary end point: ED transfer during 12-mo follow-up<sup>a</sup></td><td>95 (16.2)</td><td>104 (12.8)</td><td>1.32 (0.83-2.09)<sup>b</sup></td><td>.24</td></tr><tr><td>Incidence rate of ED transfer during 12-mo follow-up for 100 person-years (95% CI)</td><td>20.06 (14.34-28.06)</td><td>16.27 (11.77-22.49)</td><td>1.23 (0.78-1.94)<sup>c</sup></td><td>.36</td></tr><tr><td>ED transfer during 18-mo follow-up</td><td>118 (20.1)</td><td>145 (17.8)</td><td>1.16 (0.71 to1.91)<sup>b</sup></td><td>.54</td></tr><tr><td>Incidence rate of ED transfer during 18-mo follow-up for 100 person-years (95% CI)</td><td>18.97 (13.55-26.55)</td><td>16.87 (12.26-23.23)</td><td>1.12 (0.71-1.77)<sup>c</sup></td><td>.61</td></tr><tr><td>ED transfer judged inappropriate by experts during 18-mo follow-up (n = 404)</td><td>46/204 (22.5)</td><td>15/200 (7.5)</td><td>3.60 (1.90-6.84)<sup>b</sup></td><td>&lt;.001</td></tr><tr><td>Incidence rate of ED transfer whatever the hospital unit during 18-mo follow-up in person-years (95% CI)</td><td>73.56 (58.95-91.79)</td><td>74.43 (60.59-91.43)</td><td>0.99 (0.73-1.33)<sup>c</sup></td><td>.93</td></tr><tr><td colspan="5">Subgroup analyses: ED transfer during 12-mo follow-up in the subgroups</td></tr><tr><td>NHs with Alzheimer disease unit (n = 558)</td><td>28/233 (12.0)</td><td>52/325 (16.0)</td><td>0.75 (0.41-1.41)<sup>b</sup></td><td>.37</td></tr><tr><td>NHs without Alzheimer disease unit (n = 843)</td><td>67/355 (18.9)</td><td>52/488 (10.7)</td><td>1.88 (1.01-3.52)<sup>b</sup></td><td>.04</td></tr><tr><td>Public NHs (n = 781)</td><td>59/402 (14.7)</td><td>55/379 (14.5)</td><td>1.00 (0.53-1.90)<sup>b</sup></td><td>.99</td></tr><tr><td>Private NHs (n = 620)</td><td>36/186 (19.4)</td><td>49/434 (11.3)</td><td>1.85 (0.97-3.55)<sup>b</sup></td><td>.06</td></tr><tr><td>Per-protocol population 1, No. (n = 1384)</td><td>576</td><td>808</td><td></td><td></td></tr><tr><td>ED transfer during 12-mo follow-up</td><td>94 (16.3)</td><td>103 (12.7)</td><td>1.34 (0.84-2.13)<sup>b</sup></td><td>.21</td></tr><tr><td>Incidence rate of ED transfer during 12-mo follow-up for 100 person-years (95% CI)</td><td>20.14 (14.38-28.22)</td><td>16.27 (11.76-22.52)</td><td>1.24 (0.79-1.95)<sup>c</sup></td><td>.35</td></tr><tr><td>ED transfer during 18-mo follow-up</td><td>116 (20.1)</td><td>144 (17.8)</td><td>1.17 (0.72-1.91)<sup>b</sup></td><td>.52</td></tr><tr><td>Incidence rate of ED transfer during 18-mo follow-up for 100 person-years (95% CI)</td><td>19.04 (13.61-26.65)</td><td>16.95 (12.32-23.32)</td><td>1.12 (0.71-1.77)<sup>c</sup></td><td>.61</td></tr><tr><td>Per-protocol population 2, No. (n = 1208)</td><td>400</td><td>808</td><td></td><td></td></tr><tr><td>ED transfer during 18-mo follow-up</td><td>71 (17.8)</td><td>144 (17.8)</td><td>0.99 (0.57-1.73)<sup>b</sup></td><td>.97</td></tr><tr><td>Incidence rate of ED transfer during 18-mo follow-up for 100 person-years (95% CI)</td><td>14.29 (9.41-21.70)</td><td>16.65 (11.84-23.41)</td><td>0.86 (0.51-1.46)<sup>c</sup></td><td>.57</td></tr></tbody></table>

Abbreviations: ED, emergency department; NH, nursing home.

<figure><img src="image_12.png" /></figure>

<footnote><sup>a</sup> The intracluster correlation coefficient indicates the similarity of measurements of participants from the same cluster with those from different clusters and was estimated at 0.1129 for the primary end point.</footnote>

<footnote><sup>b</sup> Odds ratio for intervention vs control.</footnote>

<footnote><sup>c</sup> Rate ratio for intervention vs control.</footnote>
no statistically significant differences in ED transfer rate (16.9% of residents diagnosed with dementia at the first MDTM vs 13.6% with no diagnosis of dementia).

We can also speculate that our neutral results may be explained by the lack of compliance to the care plan and recommendations proposed by the MDTMs by the residents' GPs. However, subgroup analyses found no statistically significant differences in ED transfer rate comparing the residents whose GP followed the recommendations of the MDTMs vs control (eTable 4 and eTable 5 in Supplement 2). Similar results were found when we compared the ED transfer rate between GP compliant residents vs GP noncompliant residents within the intervention group (eTable 6 and eTable 7 in Supplement 2). In our study, we did not collect data on the compliance of the NH staff to the care plan and recommendations proposed by the MDTMs.

Our study also suggests that the probability of at least 1 inappropriate hospitalization was significantly higher in the intervention group than in the control group (Table 4). These results suggest that the dementia screening process in the intervention group did not influence the probability of ED transfer, whatever the final diagnosis and the care plan proposed during the MDTM. The reason why residents in the intervention group were statistically more often transferred inappropriately to the ED (whatever the final diagnosis of dementia) remains unclear, but supports the suggestion that too much medication may be harmful in this population.¹⁸ However, this finding must be interpreted with caution because it consisted of an exploratory analysis performed in a non-randomly selected subgroup of participants and was restricted by data availability (only participants whose hospitalization report was available were included in this analysis).

Current evidence and expert opinion indicate that person-centered care and dementia care mapping in patients with Alzheimer disease improve the management of symptoms such as behavioral disturbances as well as clinical outcomes such as NH admission.¹ However, these findings were made in community-dwelling patients¹⁹ rather than NH residents with severe dementia or disability. In this specific NH population, this approach may be less beneficial or even pointless. There is growing concern in the scientific community about overdiagnosis or screening programs that diagnose diseases that would not cause harm to the patient. One could argue that the residents with dementia were not previously diagnosed because no clinically significant problem arose from their disease. Possibly, after systematic screening, diagnosis of dementia may have resulted in overuse of pharmaceutical agents that endangered the residents' health rather than enhancing it, and in performance of brain imaging or blood tests that raised the risk of new diagnoses and new investigations, thus distressing the resident, their relatives, and the NH staff; incurring unnecessary expense; and increasing the rate of inappropriate ED transfer. This may have occurred in particular when NH staff were not trained in dealing with people with dementia (as suggested by our exploratory results in NHs without a special Alzheimer disease care unit) (Table 4) and it may also have diverted the already stretched human resources of the NH to nonuseful tasks.

## Limitations

To our knowledge, the IDEM study is the largest randomized clinical trial to examine the benefit of systematic dementia screening in older people. However, several limitations of the study should be noted. First, IDEM was a national multicenter study in which NHs took part on a voluntary basis. They were not representative of all NHs. However, it seems unlikely that the same intervention in nonvolunteering NHs would have resulted in better outcome. Second, owing to the constraints of the study, its long duration, and NH staff turnover, 25 NHs withdrew their participation during the first 3 months (preselection period), resulting in an underpowered sample size. The initial objective was to include 2000 residents to have 80% power to detect a 30% reduction assumption of ED transfer rate in the intervention group. Whether higher recruitment would have resulted in a significantly lower rate of ED transfers in the interventional group remains unknown. However, the observed trend of higher ED transfer in the intervention group makes this hypothesis unlikely.

We did not perform any interim analysis for this nonpharmacologic treatment intervention, as interim analysis was not planned at the beginning of the trial. Given the insufficient number of

<figure><img src="image_12.png" /></figure>
no statistically significant differences in ED transfer rate (16.9% of residents diagnosed with dementia at the first MDTM vs 13.6% with no diagnosis of dementia).

We can also speculate that our neutral results may be explained by the lack of compliance to the care plan and recommendations proposed by the MDTMs by the residents' GPs. However, subgroup analyses found no statistically significant differences in ED transfer rate comparing the residents whose GP followed the recommendations of the MDTMs vs control (eTable 4 and eTable 5 in Supplement 2). Similar results were found when we compared the ED transfer rate between GP compliant residents vs GP noncompliant residents within the intervention group (eTable 6 and eTable 7 in Supplement 2). In our study, we did not collect data on the compliance of the NH staff to the care plan and recommendations proposed by the MDTMs.

Our study also suggests that the probability of at least 1 inappropriate hospitalization was significantly higher in the intervention group than in the control group (Table 4). These results suggest that the dementia screening process in the intervention group did not influence the probability of ED transfer, whatever the final diagnosis and the care plan proposed during the MDTM. The reason why residents in the intervention group were statistically more often transferred inappropriately to the ED (whatever the final diagnosis of dementia) remains unclear, but supports the suggestion that too much medication may be harmful in this population.¹⁸ However, this finding must be interpreted with caution because it consisted of an exploratory analysis performed in a non-randomly selected subgroup of participants and was restricted by data availability (only participants whose hospitalization report was available were included in this analysis).

Current evidence and expert opinion indicate that person-centered care and dementia care mapping in patients with Alzheimer disease improve the management of symptoms such as behavioral disturbances as well as clinical outcomes such as NH admission.¹ However, these findings were made in community-dwelling patients¹⁹ rather than NH residents with severe dementia or disability. In this specific NH population, this approach may be less beneficial or even pointless. There is growing concern in the scientific community about overdiagnosis or screening programs that diagnose diseases that would not cause harm to the patient. One could argue that the residents with dementia were not previously diagnosed because no clinically significant problem arose from their disease. Possibly, after systematic screening, diagnosis of dementia may have resulted in overuse of pharmaceutical agents that endangered the residents' health rather than enhancing it, and in performance of brain imaging or blood tests that raised the risk of new diagnoses and new investigations, thus distressing the resident, their relatives, and the NH staff; incurring unnecessary expense; and increasing the rate of inappropriate ED transfer. This may have occurred in particular when NH staff were not trained in dealing with people with dementia (as suggested by our exploratory results in NHs without a special Alzheimer disease care unit) (Table 4) and it may also have diverted the already stretched human resources of the NH to nonuseful tasks.

## Limitations

To our knowledge, the IDEM study is the largest randomized clinical trial to examine the benefit of systematic dementia screening in older people. However, several limitations of the study should be noted. First, IDEM was a national multicenter study in which NHs took part on a voluntary basis. They were not representative of all NHs. However, it seems unlikely that the same intervention in nonvolunteering NHs would have resulted in better outcome. Second, owing to the constraints of the study, its long duration, and NH staff turnover, 25 NHs withdrew their participation during the first 3 months (preselection period), resulting in an underpowered sample size. The initial objective was to include 2000 residents to have 80% power to detect a 30% reduction assumption of ED transfer rate in the intervention group. Whether higher recruitment would have resulted in a significantly lower rate of ED transfers in the interventional group remains unknown. However, the observed trend of higher ED transfer in the intervention group makes this hypothesis unlikely.

We did not perform any interim analysis for this nonpharmacologic treatment intervention, as interim analysis was not planned at the beginning of the trial. Given the insufficient number of

<figure><img src="image_13.png" /></figure>
participants included, a 12-month interim analysis could have been relevant; however, owing to the
expected insufficient number of participants, we opted for a longer period of exposure to the
intervention (adding a second MDTM) and a longer-term (18-month) outcome measure.

The data for staff to resident ratio for each NH were not collected in the study. It would have
been interesting to describe the exact typology of the staff in the different NHs. However, in France
we have indicators of care load (GMP, an NH level-of-dependence score; and PMP, an NH comorbidity
score), which are proxies defining the staffing requirements of the different structures. In this study,
we collected GMP. Despite a comparable GMP in both groups at baseline (Table 1), we cannot exclude
a disparity in the distribution of the different trades between the 2 groups.

Conclusions

In conclusion, this study does not preclude benefits from the diagnosis of dementia currently made
in residents before or after NH admission. However, our results do not support the recommendations
for systematic screening of all cases of dementia in NH.

ARTICLE INFORMATION

**Accepted for Publication:** December 15, 2019.

**Published:** February 26, 2020. doi:10.1001/jamanetworkopen.2020.0049

**Open Access:** This is an open access article distributed under the terms of the **CC-BY License**. © 2020 Rolland Y et al. JAMA Network Open.

**Corresponding Author:** Neda Tavassoli, PharmD, PhD, Équipe Régionale Vieillissement et Prévention de la Dépendance (ERVPD), La Cité de la Santé, Bâtiment Ex-Biochimie, Hôpital La Grave, Place Lange, TSA 60033, 31059 Toulouse Cedex 9, France (tavassoli.n@chu-toulouse.fr).

**Author Affiliations:** Gérontopôle de Toulouse, Département de Médecine Interne et Gérontologie Clinique, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France (Rolland, Tavassoli, de Souto Barreto, Perrin, Laffon de Mazières, Hermabessière, Vellas, Andrieu); Équipe Régionale Vieillissement et Prévention de la Dépendance (ERVPD), Gérontopôle de Toulouse, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France (Rolland, Tavassoli, Vellas); UMR 1027, INSERM-Université de Toulouse III, Toulouse, France (Rolland, de Souto Barreto, Vellas, Andrieu); LIRAES (EA 4470) & Chaire AGEINOMIX, Université Paris Descartes Sorbonne Paris Cité, Paris, France (Rapp); Unité de Soutien Méthodologique à la Recherche, Centre Hospitalier Universitaire de Toulouse, Toulouse, France (Tournay, Andrieu); Service d'Epidémiologie, Unité de Soutien Méthodologique à la Recherche, Centre Hospitalier Universitaire de Toulouse, Toulouse, France (Andrieu).

**Author Contributions:** Drs Rolland and Tavassoli had full access to all of the data in the study and take
responsibility for the integrity of the data and the accuracy of the data analysis.

**Concept and design:** Rolland, Tavassoli, Andrieu.

**Acquisition, analysis, or interpretation of data:** All authors.

**Drafting of the manuscript:** Rolland, Tavassoli, Rapp.

**Critical revision of the manuscript for important intellectual content:** All authors.

**Statistical analysis:** Rapp, Tournay.

**Obtained funding:** Rolland.

**Administrative, technical, or material support:** Rolland, Tavassoli, Laffon de Mazières.

**Supervision:** Rolland, Tavassoli, Rapp.

**Conflict of Interest Disclosures:** Dr Andrieu reported receiving grants from EU-FP7, EU-H2020, and EU-JPND; grants and personal fees from Nestle; an award from Harmonie Mutuelle; and an education grant from MSD outside the submitted work. No other disclosures were reported.

**Funding/Support:** The IDEM (Impact of Systematic Tracking of Dementia Cases on the Rate of Hospitalization in Emergency Care Units) study was supported by grants from the French Ministry of Health (PHRC 2009, No. 0910701). The promotion of this study was supported by the University Hospital Centre of Toulouse.

<figure><img src="image_13.png" /></figure>
participants included, a 12-month interim analysis could have been relevant; however, owing to the
expected insufficient number of participants, we opted for a longer period of exposure to the
intervention (adding a second MDTM) and a longer-term (18-month) outcome measure.

The data for staff to resident ratio for each NH were not collected in the study. It would have
been interesting to describe the exact typology of the staff in the different NHs. However, in France
we have indicators of care load (GMP, an NH level-of-dependence score; and PMP, an NH comorbidity
score), which are proxies defining the staffing requirements of the different structures. In this study,
we collected GMP. Despite a comparable GMP in both groups at baseline (Table 1), we cannot exclude
a disparity in the distribution of the different trades between the 2 groups.

Conclusions

In conclusion, this study does not preclude benefits from the diagnosis of dementia currently made
in residents before or after NH admission. However, our results do not support the recommendations
for systematic screening of all cases of dementia in NH.

ARTICLE INFORMATION

**Accepted for Publication:** December 15, 2019.

**Published:** February 26, 2020. doi:10.1001/jamanetworkopen.2020.0049

**Open Access:** This is an open access article distributed under the terms of the **CC-BY License**. © 2020 Rolland Y et al. JAMA Network Open.

**Corresponding Author:** Neda Tavassoli, PharmD, PhD, Équipe Régionale Vieillissement et Prévention de la Dépendance (ERVPD), La Cité de la Santé, Bâtiment Ex-Biochimie, Hôpital La Grave, Place Lange, TSA 60033, 31059 Toulouse Cedex 9, France (tavassoli.n@chu-toulouse.fr).

**Author Affiliations:** Gérontopôle de Toulouse, Département de Médecine Interne et Gérontologie Clinique, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France (Rolland, Tavassoli, de Souto Barreto, Perrin, Laffon de Mazières, Hermabessière, Vellas, Andrieu); Équipe Régionale Vieillissement et Prévention de la Dépendance (ERVPD), Gérontopôle de Toulouse, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France (Rolland, Tavassoli, Vellas); UMR 1027, INSERM-Université de Toulouse III, Toulouse, France (Rolland, de Souto Barreto, Vellas, Andrieu); LIRAES (EA 4470) & Chaire AGEINOMIX, Université Paris Descartes Sorbonne Paris Cité, Paris, France (Rapp); Unité de Soutien Méthodologique à la Recherche, Centre Hospitalier Universitaire de Toulouse, Toulouse, France (Tournay, Andrieu); Service d'Epidémiologie, Unité de Soutien Méthodologique à la Recherche, Centre Hospitalier Universitaire de Toulouse, Toulouse, France (Andrieu).

**Author Contributions:** Drs Rolland and Tavassoli had full access to all of the data in the study and take
responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Rolland, Tavassoli, Andrieu.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Rolland, Tavassoli, Rapp.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Rapp, Tournay.

Obtained funding: Rolland.

Administrative, technical, or material support: Rolland, Tavassoli, Laffon de Mazières.

Supervision: Rolland, Tavassoli, Rapp.

**Conflict of Interest Disclosures:** Dr Andrieu reported receiving grants from EU-FP7, EU-H2020, and EU-JPND; grants and personal fees from Nestle; an award from Harmonie Mutuelle; and an education grant from MSD outside the submitted work. No other disclosures were reported.

**Funding/Support:** The IDEM (Impact of Systematic Tracking of Dementia Cases on the Rate of Hospitalization in Emergency Care Units) study was supported by grants from the French Ministry of Health (PHRC 2009, No. 0910701). The promotion of this study was supported by the University Hospital Centre of Toulouse.

<figure><img src="image_14.png" /></figure>
**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Additional Information:** We disseminated the results to nursing home staff (directors and coordinating physicians) who participated in the study.

**Data Sharing Statement:** See Supplement 3.

**Additional Contributions:** We thank the members of the IDEM study team, the coordinating physician-investigators, the expert physicians of the memory clinics, and persons from different institutions for their participation in the study.

REFERENCES

1. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. *Lancet*. 2017;390 (10113):2673-2734. doi:10.1016/S0140-6736(17)31363-6

2. Cherubini A, Ruggiero C, Dell'Aquila G, et al. Underrecognition and undertreatment of dementia in Italian nursing homes. *J Am Med Dir Assoc*. 2012;13(8):759.e7-759.e13. doi:10.1016/j.jamda.2012.05.015

3. Magsi H, Malloy T. Underrecognition of cognitive impairment in assisted living facilities. *J Am Geriatr Soc*. 2005; 53(2):295-298. doi:10.1111/j.1532-5415.2005.53117.x

4. Rolland Y, Andrieu S, Crochard A, Goni S, Hein C, Vellas B. Psychotropic drug consumption at admission and discharge of nursing home residents. *J Am Med Dir Assoc*. 2012;13(4):407.e7-407.e12. doi:10.1016/j.jamda.2011.12.056

5. Gordon M, Klapecki KC, Wilson DB. Emergency care and the patient in the long-term care facility. *CMAJ*. 1991; 145(1):19-21.

6. Kayser-Jones JS, Wiener CL, Barbaccia JC. Factors contributing to the hospitalization of nursing home residents. *Gerontologist*. 1989;29(4):502-510. doi:10.1093/geront/29.4.502

7. Kerr HD, Byrd JC. Nursing home patients transferred by ambulance to a VA emergency department. *J Am Geriatr Soc*. 1991;39(2):132-136. doi:10.1111/j.1532-5415.1991.tb01614.x

8. Circulaire interministérielle DGCS/SD3/DSS/SD1 n° 2013/418 du 6 décembre 2013 relative à la mise en œuvre du décret n° 2013-22 du 8 janvier 2013 relatif à l'évaluation et à la validation du niveau de perte d'autonomie et des besoins en soins des personnes hébergées dans les établissements d'hébergement pour personnes âgées dépendantes et fixant la composition et le fonctionnement de la commission régionale de coordination médicale mentionnée à l'article L.314-9 du code de l'action sociale et des familles. https://solidarites-sante.gouv.fr/fichiers/bo/2014/14-01/ste_20140001_0000_0074.pdf. Accessed March 2, 2019.

9. Rolland Y, Tavassoli N, Gillette-Guyonnet S, et al; IDEM investigators. Multidisciplinary team meetings (MDTM) in detection of Alzheimer's disease: data from the IDEM study. *J Nutr Health Aging*. 2013;17(2):137-141. doi:10.1007/s12603-012-0403-7

10. Rolland Y, Abellan van Kan G, Hermabessiere S, Gerard S, Guyonnet Gillette S, Vellas B. Descriptive study of nursing home residents from the REHPA network. *J Nutr Health Aging*. 2009;13(8):679-683. doi:10.1007/s12603-009-0197-4

11. Barker WH, Zimmer JG, Hall WJ, Ruff BC, Freundlich CB, Eggert GM. Rates, patterns, causes, and costs of hospitalization of nursing home residents: a population-based study. *Am J Public Health*. 1994;84(10):1615-1620. doi:10.2105/AJPH.84.10.1615

12. Intrator O, Zinn J, Mor V. Nursing home characteristics and potentially preventable hospitalizations of long-stay residents. *J Am Geriatr Soc*. 2004;52(10):1730-1736. doi:10.1111/j.1532-5415.2004.52469.x

13. LaMantia MA, Lane KA, Tu W, Carnahan JL, Messina F, Unroe KT. Patterns of emergency department use among long-stay nursing home residents with differing levels of dementia severity. *J Am Med Dir Assoc*. 2016;17 (6):541-546. doi:10.1016/j.jamda.2016.02.011

14. Shenkin SD, Russ TC, Ryan TM, MacLullich AM. Screening for dementia and other causes of cognitive impairment in general hospital in-patients. *Age Ageing*. 2014;43(2):166-168. doi:10.1093/ageing/aft184

15. Ouslander JG, Weinberg AD, Phillips V. Inappropriate hospitalization of nursing facility residents: a symptom of a sick system of care for frail older people. *J Am Geriatr Soc*. 2000;48(2):230-231. doi:10.1111/j.1532-5415.2000.tb03919.x

16. Callahan CM, Arling G, Tu W, et al. Transitions in care for older adults with and without dementia. *J Am Geriatr Soc*. 2012;60(5):813-820. doi:10.1111/j.1532-5415.2012.03905.x

<figure><img src="image_14.png" /></figure>
**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Additional Information:** We disseminated the results to nursing home staff (directors and coordinating physicians) who participated in the study.

**Data Sharing Statement:** See Supplement 3.

**Additional Contributions:** We thank the members of the IDEM study team, the coordinating physician-investigators, the expert physicians of the memory clinics, and persons from different institutions for their participation in the study.

REFERENCES

1. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. *Lancet*. 2017;390 (10113):2673-2734. doi:10.1016/S0140-6736(17)31363-6

2. Cherubini A, Ruggiero C, Dell'Aquila G, et al. Underrecognition and undertreatment of dementia in Italian nursing homes. *J Am Med Dir Assoc*. 2012;13(8):759.e7-759.e13. doi:10.1016/j.jamda.2012.05.015

3. Magsi H, Malloy T. Underrecognition of cognitive impairment in assisted living facilities. *J Am Geriatr Soc*. 2005; 53(2):295-298. doi:10.1111/j.1532-5415.2005.53117.x

4. Rolland Y, Andrieu S, Crochard A, Goni S, Hein C, Vellas B. Psychotropic drug consumption at admission and discharge of nursing home residents. *J Am Med Dir Assoc*. 2012;13(4):407.e7-407.e12. doi:10.1016/j.jamda.2011.12.056

5. Gordon M, Klapecki KC, Wilson DB. Emergency care and the patient in the long-term care facility. *CMAJ*. 1991; 145(1):19-21.

6. Kayser-Jones JS, Wiener CL, Barbaccia JC. Factors contributing to the hospitalization of nursing home residents. *Gerontologist*. 1989;29(4):502-510. doi:10.1093/geront/29.4.502

7. Kerr HD, Byrd JC. Nursing home patients transferred by ambulance to a VA emergency department. *J Am Geriatr Soc*. 1991;39(2):132-136. doi:10.1111/j.1532-5415.1991.tb01614.x

8. Circulaire interministérielle DGCS/SD3/DSS/SD1 n° 2013/418 du 6 décembre 2013 relative à la mise en œuvre du décret n° 2013-22 du 8 janvier 2013 relatif à l'évaluation et à la validation du niveau de perte d'autonomie et des besoins en soins des personnes hébergées dans les établissements d'hébergement pour personnes âgées dépendantes et fixant la composition et le fonctionnement de la commission régionale de coordination médicale mentionnée à l'article L.314-9 du code de l'action sociale et des familles. https://solidarites-sante.gouv.fr/fichiers/bo/2014/14-01/ste_20140001_0000_0074.pdf. Accessed March 2, 2019.

9. Rolland Y, Tavassoli N, Gillette-Guyonnet S, et al; IDEM investigators. Multidisciplinary team meetings (MDTM) in detection of Alzheimer's disease: data from the IDEM study. *J Nutr Health Aging*. 2013;17(2):137-141. doi:10.1007/s12603-012-0403-7

10. Rolland Y, Abellan van Kan G, Hermabessiere S, Gerard S, Guyonnet Gillette S, Vellas B. Descriptive study of nursing home residents from the REHPA network. *J Nutr Health Aging*. 2009;13(8):679-683. doi:10.1007/s12603-009-0197-4

11. Barker WH, Zimmer JG, Hall WJ, Ruff BC, Freundlich CB, Eggert GM. Rates, patterns, causes, and costs of hospitalization of nursing home residents: a population-based study. *Am J Public Health*. 1994;84(10):1615-1620. doi:10.2105/AJPH.84.10.1615

12. Intrator O, Zinn J, Mor V. Nursing home characteristics and potentially preventable hospitalizations of long-stay residents. *J Am Geriatr Soc*. 2004;52(10):1730-1736. doi:10.1111/j.1532-5415.2004.52469.x

13. LaMantia MA, Lane KA, Tu W, Carnahan JL, Messina F, Unroe KT. Patterns of emergency department use among long-stay nursing home residents with differing levels of dementia severity. *J Am Med Dir Assoc*. 2016;17 (6):541-546. doi:10.1016/j.jamda.2016.02.011

14. Shenkin SD, Russ TC, Ryan TM, MacLullich AM. Screening for dementia and other causes of cognitive impairment in general hospital in-patients. *Age Ageing*. 2014;43(2):166-168. doi:10.1093/ageing/aft184

15. Ouslander JG, Weinberg AD, Phillips V. Inappropriate hospitalization of nursing facility residents: a symptom of a sick system of care for frail older people. *J Am Geriatr Soc*. 2000;48(2):230-231. doi:10.1111/j.1532-5415.2000.tb03919.x

16. Callahan CM, Arling G, Tu W, et al. Transitions in care for older adults with and without dementia. *J Am Geriatr Soc*. 2012;60(5):813-820. doi:10.1111/j.1532-5415.2012.03905.x

<figure><img src="image_15.png" /></figure>
17. de Souto Barreto P, Lapeyre-Mestre M, Vellas B, Rolland Y. Multimorbidity type, hospitalizations and emergency department visits among nursing home residents: a preliminary study. *J Nutr Health Aging*. 2014;18: 705-709.

18. Brunet MD, McCartney M, Heath I, et al. There is no evidence base for proposed dementia screening. *BMJ*. 2012;345:e8588. doi:10.1136/bmj.e8588

19. Reilly S, Miranda-Castillo C, Malouf R, et al. Case management approaches to home support for people with dementia. *Cochrane Database Syst Rev*. 2015;1(1):CD008345. doi:10.1002/14651858.CD008345.pub2

## SUPPLEMENT 1.

### Trial Protocol

## SUPPLEMENT 2.

eAppendix 1. Role of Coordinating Physician in NH

eAppendix 2. Stratification Criteria of Cluster Randomization

eAppendix 3. GIR Score

eAppendix 4. Inclusion and Visits in NHs

eAppendix 5. Content of MDTM

eAppendix 6. Classification of Hospitalizations as Appropriate or Inappropriate

eAppendix 7. Per-protocol Analyses

eAppendix 8. Exploratory Analyses

eAppendix 9. Results of Per-protocol Analyses

eAppendix 10. Results of Exploratory Analyses

eReferences.

eFigure. Study Flow-chart

eTable 1. Comprehensive Geriatric Assessment at Inclusion and End of Study Visits (mITT Population)

eTable 2. Assessment of Intervention Effect on Primary and Secondary Endpoints Observed in the 64 Nursing Homes in Person-Years (mITT Population, N=1401)

eTable 3. Estimation and Test of Effect of Dementia Diagnosis on Risk of ED Transfer During 12-Month Follow-up (mITT Population) (N=1401)

eTable 4. Assessment of Effect of Following the Recommendations of the First MDTM by GP on Risk of ED Transfer During 12-Month and 18-Month Follow-up (Subjects With MDTM1 Recommendations Followed by GPs Versus Control) (N=1086)

eTable 5. Assessment of Effect of Following the Recommendations of the First and the Second MDTMs by GP on Risk of ED Transfer During 18-Month Follow-up (Subjects With Two MDTMs Recommendations Followed by GPs Versus Control) (N=960)

eTable 6. Assessment of Effect of Following the Recommendations of the First MDTM by GP on Risk of ED Transfer During 12-Month and 18-Month Follow-up (Subjects With MDTM1 Recommendations Followed by GPs Versus Those With MDTM1 Recommendations Not Followed by GPs) (N=445)

eTable 7. Assessment of Effect of Following the Recommendations of the First and the Second MDTMs by GP on Risk of ED Transfer During 18-Month Follow-up (Subjects With Two MDTMs Recommendations Followed by GPs Versus Those With Two MDTMs Recommendations Not Followed by GPs) (N=371)

## SUPPLEMENT 3.

### Data Sharing Statement

<figure><img src="image_15.png" /></figure>
17. de Souto Barreto P, Lapeyre-Mestre M, Vellas B, Rolland Y. Multimorbidity type, hospitalizations and emergency department visits among nursing home residents: a preliminary study. *J Nutr Health Aging*. 2014;18: 705-709.

18. Brunet MD, McCartney M, Heath I, et al. There is no evidence base for proposed dementia screening. *BMJ*. 2012;345:e8588. doi:10.1136/bmj.e8588

19. Reilly S, Miranda-Castillo C, Malouf R, et al. Case management approaches to home support for people with dementia. *Cochrane Database Syst Rev*. 2015;1(1):CD008345. doi:10.1002/14651858.CD008345.pub2

## SUPPLEMENT 1.

### Trial Protocol

## SUPPLEMENT 2.

eAppendix 1. Role of Coordinating Physician in NH

eAppendix 2. Stratification Criteria of Cluster Randomization

eAppendix 3. GIR Score

eAppendix 4. Inclusion and Visits in NHs

eAppendix 5. Content of MDTM

eAppendix 6. Classification of Hospitalizations as Appropriate or Inappropriate

eAppendix 7. Per-protocol Analyses

eAppendix 8. Exploratory Analyses

eAppendix 9. Results of Per-protocol Analyses

eAppendix 10. Results of Exploratory Analyses

eReferences.

eFigure. Study Flow-chart

eTable 1. Comprehensive Geriatric Assessment at Inclusion and End of Study Visits (mITT Population)

eTable 2. Assessment of Intervention Effect on Primary and Secondary Endpoints Observed in the 64 Nursing Homes in Person-Years (mITT Population, N=1401)

eTable 3. Estimation and Test of Effect of Dementia Diagnosis on Risk of ED Transfer During 12-Month Follow-up (mITT Population) (N=1401)

eTable 4. Assessment of Effect of Following the Recommendations of the First MDTM by GP on Risk of ED Transfer During 12-Month and 18-Month Follow-up (Subjects With MDTM1 Recommendations Followed by GPs Versus Control) (N=1086)

eTable 5. Assessment of Effect of Following the Recommendations of the First and the Second MDTMs by GP on Risk of ED Transfer During 18-Month Follow-up (Subjects With Two MDTMs Recommendations Followed by GPs Versus Control) (N=960)

eTable 6. Assessment of Effect of Following the Recommendations of the First MDTM by GP on Risk of ED Transfer During 12-Month and 18-Month Follow-up (Subjects With MDTM1 Recommendations Followed by GPs Versus Those With MDTM1 Recommendations Not Followed by GPs) (N=445)

eTable 7. Assessment of Effect of Following the Recommendations of the First and the Second MDTMs by GP on Risk of ED Transfer During 18-Month Follow-up (Subjects With Two MDTMs Recommendations Followed by GPs Versus Those With Two MDTMs Recommendations Not Followed by GPs) (N=371)

## SUPPLEMENT 3.

### Data Sharing Statement

<figure><img src="image_16.png" /></figure>